0001932393-23-000125 | 10-Q | XBRL Viewer | GE Healthcare Technologies INC

Print Document View Excel Document

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Fair Values (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Derivative [Line Items]
Gross Notional	$ 9,083	$ 8,488
Fair Value – Assets	126	66
Fair Value – Liabilities	215	209
Designated as hedging instrument \| Cash flow hedges
Derivative [Line Items]
Gross Notional	1,113	1,240
Fair Value – Assets	41	32
Fair Value – Liabilities	35	53
Designated as hedging instrument \| Cash flow hedges \| Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	1,113	1,240
Fair Value – Assets	41	32
Fair Value – Liabilities	35	53
Designated as hedging instrument \| Net investment hedges
Derivative [Line Items]
Gross Notional	3,093	2,132
Fair Value – Assets	32	0
Fair Value – Liabilities	150	111
Designated as hedging instrument \| Net investment hedges \| Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	871
Designated as hedging instrument \| Net investment hedges \| Cross-currency swaps
Derivative [Line Items]
Gross Notional	2,126	2,132
Fair Value – Assets	22	0
Fair Value – Liabilities	141	111
Designated as hedging instrument \| Net investment hedges \| Foreign currency exchange contracts and options
Derivative [Line Items]
Gross Notional	967	0
Fair Value – Assets	10	0
Fair Value – Liabilities	9	0
Not designated as hedging instrument
Derivative [Line Items]
Gross Notional	4,877	5,116
Fair Value – Assets	53	34
Fair Value – Liabilities	30	45
Not designated as hedging instrument \| Foreign currency exchange contracts
Derivative [Line Items]
Gross Notional	4,436	4,456
Fair Value – Assets	13	9
Fair Value – Liabilities	29	20
Not designated as hedging instrument \| Other derivatives
Derivative [Line Items]
Gross Notional	441	660
Fair Value – Assets	40	25
Fair Value – Liabilities	$ 1	$ 25

Insider Trading Arrangements	3 Months Ended
Insider Trading Arrangements	Sep. 30, 2023
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

SEGMENT INFORMATION

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

SEGMENT INFORMATION

GE HealthCare’s operations are organized and managed through four reportable segments: Imaging, Ultrasound, Patient Care Solutions (“PCS”), and Pharmaceutical Diagnostics (“PDx”). These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments. A description of our reportable segments has been provided in the “Business” section of our Annual Report on Form 10-K for the year ended December 31, 2022.

The performance of these segments is principally measured based on Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as Income from continuing operations before income taxes in our Condensed Consolidated and Combined Statements of Income excluding the impact of the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition related benefits (charges), gain (loss) of business and asset dispositions, spin-off and separation costs, amortization of acquisition-related intangible assets, and investment revaluation gain (loss).


Total Revenues by Segment
	For the three months ended September 30				For the nine months ended September 30

	2023		2022		2023		2022
Imaging:
Radiology	$	2,237	$	2,118	$	6,552	$	6,100
Interventional Guidance	398		398		1,199		1,176
Total Imaging	2,635		2,516		7,751		7,276
Total Ultrasound	815		823		2,513		2,466
PCS:
Monitoring Solutions	573		506		1,688		1,539
Life Support Solutions	191		195		627		591
Total PCS	764		701		2,315		2,130
Total PDx	589		522		1,715		1,485
Other(1)	19		14		52		46
Total revenues	$	4,822	$	4,576	$	14,346	$	13,403

(1) Financial information not presented within the reportable segments, shown within the Other category, represents the HealthCare Financial Services (“HFS”) business which does not meet the definition of an operating segment.


Segment EBIT
	For the three months ended September 30				For the nine months ended September 30
	2023		2022		2023		2022
Segment EBIT
Imaging	$	318	$	267	$	787	$	779
Ultrasound	179		211		577		623
PCS	80		65		273		211
PDx	166		159		473		411
Other(1)	1		(2)		9		(7)
	744		700		2,119		2,017
Restructuring costs	(3)		(88)		(34)		(110)
Acquisition and disposition related benefits (charges)	14		49		15		20
Gain (loss) of business and asset dispositions	—		(2)		—		1
Spin-Off and separation costs	(45)		(7)		(175)		(7)
Amortization of acquisition-related intangible assets	(32)		(28)		(95)		(90)
Investment revaluation gain (loss)	2		(1)		1		(23)
Interest and other financial charges – net	(138)		(2)		(411)		(18)
Non-operating benefit income (costs)	94		1		332		4
Income from continuing operations before income taxes	$	636	$	622	$	1,752	$	1,794

(1) Financial information not presented within the reportable segments, shown within the Other category, represents the HFS business and certain other business activities which do not meet the definition of an operating segment.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-15

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-42

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-40

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//280/tableOfContent

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-26

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-34

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

+ Details

POSTRETIREMENT BENEFIT PLANS - Schedule of Defined Benefit Plans (Details) $ in Millions	Jan. 01, 2023 USD ($)
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	$ 22,906
Unrecognized gain to be recorded in AOCI	2,481
Net Benefit Liability
Projected benefit obligations	22,953
Fair value of assets	18,908
Net liability	4,045
Defined benefit plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	21,696
Unrecognized gain to be recorded in AOCI	1,258
Net Benefit Liability
Projected benefit obligations	21,743
Fair value of assets	18,908
Net liability	2,835
Other postretirement plans
Accumulated Benefit Obligations and Unrecognized Gain
Accumulated benefit obligations	1,210
Unrecognized gain to be recorded in AOCI	1,223
Net Benefit Liability
Projected benefit obligations	1,210
Fair value of assets	0
Net liability	$ 1,210

- Definition

Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.

+ References + Details

Cover - shares	9 Months Ended
Cover - shares	Sep. 30, 2023	Oct. 24, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-41528
Entity Registrant Name	GE HEALTHCARE TECHNOLOGIES INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	88-2515116
Entity Address, Address Line One	500 W. Monroe Street
Entity Address, City or Town	Chicago
Entity Address, State or Province	IL
Entity Address, Postal Zip Code	60661
City Area Code	833
Local Phone Number	735-1139
Title of 12(b) Security	Common stock, par value $0.01 per share
Trading Symbol	GEHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		455,242,974
Amendment Flag	false
Entity Central Index Key	0001932393
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--12-31

EARNINGS PER SHARE (Tables)

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

Schedule of Earnings per Share


Earnings Per Share
	For the three months ended September 30				For the nine months ended September 30
(In millions, except per share amounts)	2023		2022		2023		2022
Numerator:
Net income from continuing operations	$	386	$	493	$	1,202	$	1,382
Net (income) loss attributable to noncontrolling interests	(7)		(6)		(33)		(32)
Net income from continuing operations attributable to GE HealthCare	379		487		1,169		1,350
Deemed preferred stock dividend of redeemable noncontrolling interest	—		—		(183)		—
Net income from continuing operations attributable to GE HealthCare common stockholders	379		487		986		1,350
Income (loss) from discontinued operations, net of taxes	(4)		—		(4)		12
Net income attributable to GE HealthCare common stockholders	$	375	$	487	$	982	$	1,362
Denominator:
Basic weighted-average shares outstanding	455		454		455		454
Dilutive effect of common stock equivalents	3		—		3		—
Diluted weighted-average shares outstanding	458		454		458		454
Basic Earnings Per Share:
Continuing operations	$	0.83	$	1.07	$	2.17	$	2.97
Discontinued operations	(0.01)		—		(0.01)		0.03
Attributable to GE HealthCare common stockholders	0.82		1.07		2.16		3.00
Diluted Earnings Per Share:
Continuing operations	$	0.83	$	1.07	$	2.16	$	2.97
Discontinued operations	(0.01)		—		(0.01)		0.03
Attributable to GE HealthCare common stockholders	0.82		1.07		2.15		3.00
Antidilutive securities(1)	4		—		4		—

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

POSTRETIREMENT BENEFIT PLANS - Narrative (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Defined Benefit Plan Disclosure [Line Items]
Defined benefit plan liability					$ 0
Plan asset or obligation reporting threshold			$ 50,000,000	$ 20,000,000
Defined benefit plan, expected future employer contributions, current year	$ 353,000,000		353,000,000
Defined benefit plan, expected future employer contributions, plans no longer disclosed	11,000,000		11,000,000
Defined contribution plan, employer contribution amount	28,000,000	$ 30,000,000	94,000,000	96,000,000
Pension plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense	(63,000,000)	2,000,000	(228,000,000)	8,000,000
Loss due to curtailment	17,000,000	0	17,000,000	0
Benefit obligation, increase for curtailment	23,000,000
AOCI, decrease due to remeasurement	305,000,000
Defined benefit plan, employer contribution amount			157,000,000
Other postretirement plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense	(21,000,000)	0	(63,000,000)	0
Loss due to curtailment	$ 0	0	0	0
Defined benefit plan, employer contribution amount			$ 102,000,000
U.S. GE Principal Pension and Principal Retiree Benefit Plans
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense		24,000,000		73,000,000
Non-U.S. GE Pension Plan
Defined Benefit Plan Disclosure [Line Items]
Net periodic postretirement benefit plan (income) expense		$ 0		$ 0

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Redeemable Noncontrolling Interest (Details) - USD ($) $ in Millions		3 Months Ended	9 Months Ended
	Jan. 03, 2023	Jun. 30, 2023	Sep. 30, 2023	Sep. 30, 2022
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Balance at beginning of period			$ 230	$ 220
Net income attributable to redeemable noncontrolling interests			28	24
Redemption value adjustments	$ 183		183	0
Distributions to and exercise of redeemable noncontrolling interests and other			(280)	(46)
Balance at end of period			161	198
Noncontrolling interest redemption payment		$ 211	$ 211	$ 0

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Cash flow hedges	$ 24	$ 31	$ 14	$ 65
Net investment hedges	$ 64	$ 0	$ (7)	$ 0

SHARE-BASED COMPENSATION (Tables)

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

Summary of Weighted Average Grant Date Fair Value and Share-Based Compensation Activity

The following tables provide the weighted average fair value of options, RSUs, and PSUs granted to employees during the nine months ended September 30, 2023 and the related weighted average stock option valuation assumptions used in the Black-Scholes model.


Weighted Average Grant Date Fair Value
(In dollars)	September 30, 2023
Stock options	$	25
RSUs	73
PSUs	85


Share-Based Compensation Activity
	Stock options						RSUs
	Shares (in thousands)	Weighted average exercise price (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding as of January 4, 2023(1)	3,738	$	90				3,551	$	58
Granted	2,156	72					1,860	73
Exercised/Vested	(524)	60					(1,201)	56
Forfeited	(128)	71					(270)	65
Expired	(200)	127					—	—
Outstanding as of September 30, 2023	5,042	$	84	6.3	$	14	3,940	$	66	1.7	$	268
Exercisable as of September 30, 2023	2,852	$	93	4.1	$	14	N/A	N/A		N/A	N/A
Expected to vest	1,721	$	72	9.3	$	—	3,363	$	59	1.7	$	229

(1) Our common stock began “regular way” trading on Nasdaq on January 4, 2023. The shares outstanding as of January 4, 2023 pertain to GE equity-based awards issued by GE in prior periods to employees of the Company that were converted to GE HealthCare equity-based awards as part of the Spin-Off.

Schedule of Stock Options Valuation Assumptions


Key Assumptions in the Black-Scholes Valuation for Stock Options
	September 30, 2023
Risk free rate	3.6		%
Dividend yield	0.01		%
Expected volatility	26.2		%
Expected term (in years)	6.2
Strike price (in dollars)	$	72

Summary of Share-Based Compensation Expense and Other Share-Based Compensation Data


Share-based Compensation Expense	For the three months ended		For the nine months ended
	September 30, 2023		September 30, 2023



Share-based compensation expense (pre-tax)	$	29	$	81
Income tax benefits	(4)		(15)
Share-based compensation expense (after-tax)	$	25	$	66


Other Share-based Compensation Data

Unrecognized compensation expense as of September 30, 2023(1)	$	174
Cash received from stock options exercised for the nine months ended September 30, 2023	31
Intrinsic value of stock options exercised and RSU/PSUs vested in the nine months ended September 30, 2023	99

(1) Amortized over a weighted average period of 2.0 years.

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Assets:
Investment securities	$ 28	$ 21
Derivatives	126	66
Liabilities:
Deferred compensation	239	64
Derivatives	215	209
Contingent consideration	49	42
Level 1
Assets:
Investment securities	28	21
Derivatives	0	0
Liabilities:
Deferred compensation	236	62
Derivatives	0	0
Contingent consideration	0	0
Level 2
Assets:
Investment securities	0	0
Derivatives	126	66
Liabilities:
Deferred compensation	3	2
Derivatives	215	203
Contingent consideration	0	0
Level 3
Assets:
Investment securities	0	0
Derivatives	0	0
Liabilities:
Deferred compensation	0	0
Derivatives	0	6
Contingent consideration	$ 49	$ 42

FINANCING RECEIVABLES

9 Months Ended

Sep. 30, 2023

Receivables [Abstract]

FINANCING RECEIVABLES


Financing Receivables
	As of
	September 30, 2023		December 31, 2022
Loans, net of deferred income	$	28	$	29
Investment in financing leases, net of deferred income	72		72
Allowance for credit losses	(3)		(4)
Current financing receivables – net(1)	97		97
Loans, net of deferred income	38		44
Investment in financing leases, net of deferred income	156		158
Allowance for credit losses	(4)		(6)
Non-current financing receivables – net(1)	$	190	$	196

(1) Current financing receivables and non-current financing receivables are recognized within All other current assets and All other assets, respectively, in the Condensed Consolidated and Combined Statements of Financial Position.

As of September 30, 2023, 6%, 5%, and 5% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2022, 7%, 6%, and 6% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

SHARE-BASED COMPENSATION - Summary of Weighted Average Grant Date Fair Value (Details) - $ / shares	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value of stock options (in dollars per share)		$ 25
RSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)	$ 73	73
PSUs
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)		$ 85

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-1D

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480483/718-10-35-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480429/718-10-50-2

+ Details

BORROWINGS

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

BORROWINGS

The Company’s borrowings include the following senior unsecured notes and credit agreements:

Senior Unsecured Notes

The Company’s long-term borrowings include $8,250 million aggregate principal amount of senior unsecured notes in six series with maturity dates ranging from 2024 through 2052 (collectively, the “Notes”). Refer to the table below for further information about the Notes.

Credit Facilities

The Company has credit agreements providing for:

•a five-year senior unsecured revolving credit facility in an aggregate committed amount of $2,500 million;

•a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $1,000 million; and

•a three-year senior unsecured term loan credit facility in an aggregate principal amount of $2,000 million (the “Term Loan Facility” and, together with the five-year revolving credit facility and the 364-day revolving credit facility, the “Credit Facilities”).

There were no outstanding amounts under the five-year revolving credit facility and 364-day revolving credit facility as of September 30, 2023 or December 31, 2022. On January 3, 2023, the Company completed a $2,000 million drawdown of the floating rate Term Loan Facility in connection with the Spin-Off from GE.

The weighted average interest rate for the Notes and our Credit Facilities for the nine months ended September 30, 2023 was 6.01%. We had no principal debt repayments on the Notes or the Term Loan Facility for the nine months ended September 30, 2023.


Long-Term Borrowings Composition
	As of
	September 30, 2023		December 31, 2022
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025	1,500		1,500
5.650% senior notes due November 15, 2027	1,750		1,750
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility	2,000		—
Other	51		38
Total principal debt issued	10,301		8,288
Less: Unamortized debt issuance costs and discounts	41		47
Less: Current portion of long-term borrowings	7		7
Long-term borrowings, net of current portion	$	10,253	$	8,234

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated derivatives contracts.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

As of September 30, 2023 and December 31, 2022, the Company had unused letters of credit, bank guarantees, bid bonds, and surety bonds of approximately $724 million and $657 million, respectively, related to certain commercial contracts. Additionally, we have approximately $39 million and $43 million of guarantees as of September 30, 2023 and December 31, 2022, respectively, primarily related to residual and credit guarantees on equipment sold to third-party finance companies. Our Condensed Consolidated and Combined Statements of Financial Position reflect a liability of $4 million and $4 million as of September 30, 2023 and December 31, 2022, respectively, related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost. See Note 13, “Commitments, Guarantees, Product Warranties, and Other Loss Contingencies” for further information on guarantee arrangements with GE.

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//470/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1B

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1C

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1E

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481139/470-20-50-1I

+ Details

REVENUE RECOGNITION

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

REVENUE RECOGNITION

REVENUE RECOGNITIONOur revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services.


Contract and Other Deferred Assets
	As of
	September 30, 2023		December 31, 2022
Contract assets	$	650	$	584
Other deferred assets	388		405
Contract and other deferred assets	1,038		989
Non-current contract assets(1)	67		37
Non-current other deferred assets(1)	88		82
Total contract and other deferred assets	$	1,193	$	1,108

(1)Non-current contract and other deferred assets are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Contract assets primarily reflect revenue recognized on contracts with customers in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.

CONTRACT LIABILITIES.

Contract liabilities primarily include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which remaining performance obligations are expected to be satisfied with our customers.

As of September 30, 2023 and December 31, 2022, contract liabilities were approximately $2,610 million and $2,526 million, respectively, of which the non-current portion of $683 million and $630 million, respectively, was recognized in All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position. Contract liabilities increased by $84 million in 2023 primarily due to an increase in customer advances as a result of the normal annual service contract billing cycle. Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $1,357 million and $1,377 million for the nine months ended September 30, 2023 and 2022, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

Remaining performance obligations represent the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the ability to cancel or terminate without incurring a substantive penalty. As of September 30, 2023, the aggregate amount of the contracted revenues allocated to our unsatisfied (or partially unsatisfied) performance obligations was $14,162 million. We expect to recognize revenue as we satisfy our remaining performance obligations as follows: a) product-related remaining performance obligations of $4,865 million of which 99% is expected to be recognized within two years, and the remaining thereafter; and b) services-related remaining performance obligations of $9,297 million of which 65% and 94% is expected to be recognized within two years and five years, respectively, and the remaining thereafter.

- Definition

The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-9

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-10

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-15

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-12

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 606
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479806/606-10-50-13

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Topic 606
-Publisher FASB
-URI https://asc.fasb.org//606/tableOfContent

+ Details

SHARE-BASED COMPENSATION

9 Months Ended

Sep. 30, 2023

Share-Based Payment Arrangement [Abstract]

SHARE-BASED COMPENSATION

We grant stock options, restricted stock units (“RSU”), and performance share units (“PSU”) to employees under the 2023 Long-Term Incentive Plan (“LTIP”). The Talent, Culture, and Compensation Committee of the Board of Directors approves grants under the LTIP. Under the LTIP, we are authorized to issue up to approximately 41 million shares. We record compensation expense for awards expected to vest over the vesting period. We estimate forfeitures based on experience and adjust expense to reflect actual forfeitures. When options are exercised, RSUs vest, and PSUs are earned, we issue shares from authorized unissued common stock.

Stock options provide employees the opportunity to purchase GE HealthCare shares in the future at the market price of our stock on the date the award is granted (the strike price). The options become exercisable over the vesting period, typically becoming fully vested in three to three and a half years, and expire ten years from the grant date if not exercised. RSUs provide an employee the right to shares of GE HealthCare stock when the restrictions lapse over the vesting period. Upon vesting, each RSU is converted into one share of GE HealthCare common stock. PSUs provide an employee with the right to receive shares of GE HealthCare stock based upon achievement of certain performance and market metrics. Upon vesting, each PSU earned is converted into one share of GE HealthCare common stock. We value stock options using a Black-Scholes option pricing model, RSUs using the market price on the grant date, and PSUs using the market price on the grant date and a Monte Carlo simulation as needed based on performance metrics.


Weighted Average Grant Date Fair Value
(In dollars)	September 30, 2023
Stock options	$	25
RSUs	73
PSUs	85


Key Assumptions in the Black-Scholes Valuation for Stock Options
	September 30, 2023
Risk free rate	3.6		%
Dividend yield	0.01		%
Expected volatility	26.2		%
Expected term (in years)	6.2
Strike price (in dollars)	$	72

For new awards granted in 2023, the expected volatility was derived from a peer group’s blended historical and implied volatility as GE HealthCare does not have sufficient historical volatility based on the expected term of the underlying options. The expected term of the stock options was determined using the simplified method. The risk-free interest rate was determined using the implied yield currently available for zero-coupon U.S. government issues with a remaining term approximating the expected life of the options. The dividend yield input was calculated using an annualized rate based on actual dividends declared.


Share-Based Compensation Activity
	Stock options						RSUs
	Shares (in thousands)	Weighted average exercise price (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)		Shares (in thousands)	Weighted average grant date fair value (in dollars)		Weighted average contractual term (in years)	Intrinsic value (in millions)
Outstanding as of January 4, 2023(1)	3,738	$	90				3,551	$	58
Granted	2,156	72					1,860	73
Exercised/Vested	(524)	60					(1,201)	56
Forfeited	(128)	71					(270)	65
Expired	(200)	127					—	—
Outstanding as of September 30, 2023	5,042	$	84	6.3	$	14	3,940	$	66	1.7	$	268
Exercisable as of September 30, 2023	2,852	$	93	4.1	$	14	N/A	N/A		N/A	N/A
Expected to vest	1,721	$	72	9.3	$	—	3,363	$	59	1.7	$	229

Total outstanding PSUs as of September 30, 2023 were 1,256 thousand shares. The intrinsic value and weighted average contractual term of PSUs outstanding were $85 million and 1.6 years, respectively.

Share-based compensation expense is recognized within Cost of products, Cost of services, SG&A, or Research and development (“R&D”), as appropriate, in the Condensed Consolidated Statement of Income.


Share-based Compensation Expense	For the three months ended		For the nine months ended
	September 30, 2023		September 30, 2023



Share-based compensation expense (pre-tax)	$	29	$	81
Income tax benefits	(4)		(15)
Share-based compensation expense (after-tax)	$	25	$	66


Other Share-based Compensation Data

Unrecognized compensation expense as of September 30, 2023(1)	$	174
Cash received from stock options exercised for the nine months ended September 30, 2023	31
Intrinsic value of stock options exercised and RSU/PSUs vested in the nine months ended September 30, 2023	99

(1) Amortized over a weighted average period of 2.0 years.

RELATED PARTIES - Narrative (Details) $ in Millions	3 Months Ended		9 Months Ended
RELATED PARTIES - Narrative (Details) $ in Millions	Sep. 30, 2023 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) director	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Related Party Transaction [Line Items]
All other assets, noncurrent	$ 2,036		$ 2,036		$ 1,024
All other liabilities, noncurrent	1,826		1,826		$ 1,603
Revenue	4,822	$ 4,576	14,346	$ 13,403
Majority shareholder \| Separation costs related to pension, benefit and contribution plans
Related Party Transaction [Line Items]
Transaction amount		59		182
Majority shareholder \| Share-based compensation expense
Related Party Transaction [Line Items]
Transaction amount		$ 19		$ 58
Related party
Related Party Transaction [Line Items]
All other assets, noncurrent	82		82
All other liabilities, noncurrent	28		28
Related party \| Transition Services Agreement
Related Party Transaction [Line Items]
Transaction amount	94		$ 286
Agreement term			36 months
Related party \| Tax Matters Agreement
Related Party Transaction [Line Items]
Period following distribution date			2 years
Directors
Related Party Transaction [Line Items]
Number of board members \| director			2
Revenue	$ 26		$ 73

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
	Feb. 17, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Consideration transferred, upfront payment				$ 147	$ 0
Contingent consideration		$ 49		49		$ 42
Goodwill		12,914		12,914		$ 12,813
Amortization of intangible assets		$ 89	$ 103	$ 278	$ 307
Caption Health
Business Acquisition [Line Items]
Percent of interest acquired	100.00%
Consideration transferred, upfront payment	$ 127
Consideration transferred, holdback payment	10
Contingent consideration	13
Goodwill	94
Intangible assets	60
Deferred tax liabilities	$ 3

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES (Tables)

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

Schedule of Product Warranties

An analysis of changes in the liability for product warranties follows.


Product Warranties
	For the nine months ended September 30
	2023		2022
Balance at beginning of period	$	193	$	161
Current-year provisions	158		182
Expenditures	(159)		(151)
Other changes	(3)		(12)
Balance at end of period	$	189	$	180

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Narrative (Details) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023 USD ($) derivative_instrument	Sep. 30, 2022 USD ($)	Sep. 30, 2023 USD ($) derivative_instrument	Sep. 30, 2022 USD ($)	Dec. 31, 2022 USD ($)
Derivative [Line Items]
AOCI, cash flow hedge cumulative net gain (loss)	$ 2		$ 2
Cash flow hedge gain to be reclassified within 12 months			10
Cash flow hedges, pre-tax gains (losses) reclassified from AOCI into earnings	(5)	$ 17	$ 22	$ 34
Maximum length of time hedged in cash flow hedge			2 years
Notional amount	9,083		$ 9,083		$ 8,488
Derivative, potential effect of rights of offset to assets and liabilities	56		56
Equity investments without readily determinable fair value	129		129		117
Estimated fair value
Derivative [Line Items]
Long-term debt	10,465		10,465		8,512
Carrying value
Derivative [Line Items]
Long-term debt	10,260		10,260		8,241
Net investment hedges \| Designated as hedging instrument
Derivative [Line Items]
Notional amount	3,093		3,093		$ 2,132
Net investment hedges \| Designated as hedging instrument \| Currency Swap
Derivative [Line Items]
Notional amount	2,126		2,126
Net investment hedges \| Designated as hedging instrument \| Foreign currency exchange contracts
Derivative [Line Items]
Notional amount	$ 871		$ 871
Net investment hedges \| Designated as hedging instrument \| Foreign currency option
Derivative [Line Items]
Number of foreign currency derivatives \| derivative_instrument	2		2

Condensed Consolidated and Combined Statements of Financial Position (Unaudited) (Parentheticals) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for credit losses	$ 91	$ 91
Common stock, par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, authorized (in shares)	1,000,000,000	1,000,000,000
Common stock, issued (in shares)	455,224,438	100
Common stock, outstanding (in shares)	455,224,438	100

RECEIVABLES (Tables)

9 Months Ended

Sep. 30, 2023

Receivables [Abstract]

Schedule of Receivables


Current Receivables
	As of
	September 30, 2023		December 31, 2022
Current customer receivables(1)	$	3,189	$	3,112
Non-income based tax receivables	165		174
Other sundry receivables	110		100
Sundry receivables	275		274
Allowance for credit losses	(91)		(91)
Total current receivables – net	$	3,373	$	3,295

(1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to current customer receivables. Balances related to chargebacks were $148 million and $157 million as of September 30, 2023 and December 31, 2022, respectively.


Long-Term Receivables
	As of
	September 30, 2023		December 31, 2022
Long-term customer receivables	$	59	$	80
Sundry receivables	79		57
Non-income based tax receivables	26		28
Supplier advances	9		11
Allowance for credit losses	(30)		(31)
Total long-term receivables – net(1)	$	143	$	145

(1) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.


Financing Receivables
	As of
	September 30, 2023		December 31, 2022
Loans, net of deferred income	$	28	$	29
Investment in financing leases, net of deferred income	72		72
Allowance for credit losses	(3)		(4)
Current financing receivables – net(1)	97		97
Loans, net of deferred income	38		44
Investment in financing leases, net of deferred income	156		158
Allowance for credit losses	(4)		(6)
Non-current financing receivables – net(1)	$	190	$	196

RESTRUCTURING AND OTHER ACTIVITIES - NET (Tables)

9 Months Ended

Sep. 30, 2023

Restructuring and Related Activities [Abstract]

Schedule of Restructuring and Related Costs


Restructuring and Other Activities
	For the three months ended September 30				For the nine months ended September 30
	2023		2022		2023		2022
Employee termination costs	$	1	$	28	$	26	$	46
Facility and other exit costs	1		38		2		42
Asset write-downs	1		22		6		22
Total restructuring and other activities – net	$	3	$	88	$	34	$	110

SHARE-BASED COMPENSATION - Summary of Other Share-Based Compensation Data (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Share-Based Payment Arrangement [Abstract]
Unrecognized compensation expense as of September 30, 2023	$ 174
Cash received from stock options exercised for the nine months ended September 30, 2023	31
Intrinsic value of stock options exercised and RSU/PSUs vested in the nine months ended September 30, 2023	$ 99
Weighted average period of recognition	2 years

SEGMENT INFORMATION - Narrative (Details)	9 Months Ended
SEGMENT INFORMATION - Narrative (Details)	Sep. 30, 2023 segment
Segment Reporting [Abstract]
Number of operating segments	4
Number of reportable segments	4

SHARE-BASED COMPENSATION - Narrative (Details) shares in Thousands, $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($) shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Number of shares authorized for issuance	41,000
Stock options
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration period	10 years
Stock options \| Minimum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years
Stock options \| Maximum
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Vesting period	3 years 6 months
Performance Shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Units outstanding (in shares)	1,256
Intrinsic value, outstanding \| $	$ 85
Weighted average remaining contractual term, outstanding	1 year 7 months 6 days

Condensed Consolidated and Combined Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows - operating activities
Net income	$ 1,198	$ 1,394
Income (loss) from discontinued operations, net of taxes	(4)	12
Net income from continuing operations	1,202	1,382
Adjustments to reconcile Net income from continuing operations to Cash from (used for) operating activities
Depreciation of property, plant, and equipment	188	169
Amortization of intangible assets	278	307
Gain on fair value remeasurement of contingent consideration	(17)	(49)
Net periodic postretirement benefit plan (income) expense	(291)	8
Postretirement plan contributions	(259)	(17)
Provision for income taxes	550	412
Share-based compensation	81	58
Cash paid during the year for income taxes	(375)	(664)
Cash paid during the year for interest	(318)	0
Changes in operating assets and liabilities, excluding the effects of acquisitions and dispositions:
Receivables	(82)	(107)
Due from related parties	9	22
Inventories	(85)	(542)
Contract and other deferred assets	(75)	(168)
Accounts payable	(93)	369
Due to related parties	(87)	(45)
Contract liabilities	69	49
All other operating activities	356	(113)
Cash from (used for) operating activities – continuing operations	1,051	1,071
Cash flows – investing activities
Additions to property, plant and equipment and internal-use software	(293)	(233)
Dispositions of property, plant, and equipment	1	3
Purchases of businesses, net of cash acquired	(147)	0
All other investing activities	(31)	(73)
Cash from (used for) investing activities – continuing operations	(470)	(303)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	(9)	8
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	2,020	3
Repayments and other reductions (maturities longer than 90 days)	(9)	(4)
Dividends paid to stockholders	(28)	0
Redemption of noncontrolling interests	(211)	0
Net transfers (to) from GE	(1,317)	(703)
All other financing activities	(24)	(89)
Cash from (used for) financing activities – continuing operations	422	(785)
Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	(34)	(40)
Increase (decrease) in cash, cash equivalents, and restricted cash	969	(57)
Cash, cash equivalents, and restricted cash at beginning of year	1,451	561
Cash, cash equivalents, and restricted cash as of September 30	$ 2,420	$ 504

LEASES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
LEASES (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Leases [Abstract]
Operating lease liability	$ 365		$ 365		$ 347
Operating lease expense	$ 54	$ 47	$ 167	$ 143

INCOME TAXES	9 Months Ended
INCOME TAXES	Sep. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Our effective income tax rate was 39.3% and 20.7% for the three months ended September 30, 2023 and 2022, respectively, and 31.4% and 23.0% for the nine months ended September 30, 2023 and 2022, respectively. The effective tax rate for 2023 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations, tax effect of foreign currency movement, withholding taxes, and state taxes. Benefit (provision) for income taxes for the three and nine months ended September 30, 2023 included $105 million of deferred tax provision associated with the Tax Matters Agreement (“TMA”) with GE including the effect of completing the 2022 GE U.S. federal tax return. In addition, Other (income) expense - net for the three and nine months ended September 30, 2023 included a $30 million benefit related to change in tax indemnities with GE also associated with the TMA and the effect of completing the 2022 GE U.S. federal tax return. For more information on the TMA, see Note 18, “Related Parties.” The effective tax rate for the nine months ended September 30, 2022 is higher than the U.S. statutory rate primarily due to the cost of global activities, including the U.S. taxation on international operations and state taxes. The effective tax rate for the three months ended September 30, 2022 is lower than the U.S. statutory rate due to tax on foreign operations offset by the cost of global activities, including the U.S. taxation on international operations and state taxes. The Company is currently being audited in a number of jurisdictions for tax years 2004-2022, including China, Egypt, France, Germany, Norway, the United Kingdom, and the U.S. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions from within “Interest and other financial charges – net” to within “Benefit (provision) for income taxes.” See Note 1, “Organization and Basis of Presentation” for further information. Post Spin-Off, the Company’s previously undistributed earnings of certain of our foreign subsidiaries are no longer indefinitely reinvested in non-U.S. businesses due to current U.S. funding needs. Therefore, in the first quarter of 2023, an incremental deferred tax liability of $30 million was recorded for withholding and other foreign taxes due upon future distribution of earnings. In addition, the Company is providing for withholding and other foreign taxes due upon future distribution of current period earnings. Also, in connection with the Spin-Off, our net deferred income tax assets increased by $3,099 million primarily due to transfers from GE, including $964 million related to pension and postretirement benefits, with the remainder primarily attributable to tax attributes that were not part of the Company’s stand-alone operations, and changes to valuation on a GE HealthCare basis.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

Condensed Consolidated and Combined Statements of Financial Position (Unaudited) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Cash, cash equivalents, and restricted cash	$ 2,418	$ 1,445
Inventories	2,128	2,155
Contract and other deferred assets	1,038	989
All other current assets	484	417
Current assets	9,468	8,318
Property, plant, and equipment – net	2,355	2,314
Goodwill	12,914	12,813
Other intangible assets – net	1,332	1,520
Deferred income taxes	4,277	1,550
All other assets	2,036	1,024
Total assets	32,382	27,539
Short-term borrowings	7	15
Accounts payable	2,774	2,944
Contract liabilities	1,927	1,896
Current liabilities	7,565	7,191
Long-term borrowings	10,253	8,234
Compensation and benefits	5,373	549
Deferred income taxes	62	370
All other liabilities	1,826	1,603
Total liabilities	25,079	17,947
Commitments and contingencies
Redeemable noncontrolling interests	161	230
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 455,224,438 shares issued and outstanding as of September 30, 2023; 100 shares issued and outstanding as of December 31, 2022	5	0
Additional paid-in capital	6,469	0
Retained earnings	937	0
Net parent investment	0	11,235
Accumulated other comprehensive income (loss) – net	(280)	(1,878)
Total equity attributable to GE HealthCare	7,131	9,357
Noncontrolling interests	11	5
Total equity	7,142	9,362
Total liabilities, redeemable noncontrolling interests, and equity	32,382	27,539
Nonrelated party
Receivables, net	3,373	3,295
All other current liabilities	2,755	2,190
Related party
Statement of Financial Position [Abstract]
All other assets	82
All other liabilities	28
Receivables, net	27	17
All other current liabilities	$ 102	$ 146

BORROWINGS (Tables)

9 Months Ended

Sep. 30, 2023

Debt Disclosure [Abstract]

Schedule of Long-Term Borrowings


Long-Term Borrowings Composition
	As of
	September 30, 2023		December 31, 2022
5.550% senior notes due November 15, 2024	$	1,000	$	1,000
5.600% senior notes due November 15, 2025	1,500		1,500
5.650% senior notes due November 15, 2027	1,750		1,750
5.857% senior notes due March 15, 2030	1,250		1,250
5.905% senior notes due November 22, 2032	1,750		1,750
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Term Loan Facility	2,000		—
Other	51		38
Total principal debt issued	10,301		8,288
Less: Unamortized debt issuance costs and discounts	41		47
Less: Current portion of long-term borrowings	7		7
Long-term borrowings, net of current portion	$	10,253	$	8,234

- Definition

Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69B
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69B

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 69E
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481568/470-20-55-69E

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.12-04(a))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-3

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-2

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482925/835-30-45-1A

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-3

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.22)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 55
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482949/835-30-55-8

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 942
-SubTopic 470
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480848/942-470-50-3

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-8

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-6

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-7

+ Details

LEASES	9 Months Ended
LEASES	Sep. 30, 2023
Leases [Abstract]
LEASES	LEASES OPERATING LEASE LIABILITIES. Operating lease liabilities recognized within All other current liabilities or All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position were $365 million and $347 million as of September 30, 2023 and December 31, 2022, respectively. Expense related to our operating lease portfolio, primarily our long-term fixed leases, was $54 million and $47 million for the three months ended September 30, 2023 and 2022, respectively, and $167 million and $143 million for the nine months ended September 30, 2023 and 2022, respectively.

POSTRETIREMENT BENEFIT PLANS

9 Months Ended

Sep. 30, 2023

Retirement Benefits [Abstract]

POSTRETIREMENT BENEFIT PLANS

PENSION BENEFITS AND RETIREE HEALTH AND LIFE BENEFITS SPONSORED BY GE, TRANSFERRED TO GE HEALTHCARE IN CONNECTION WITH THE SPIN-OFF.

Certain GE HealthCare employees were covered under various pension and retiree health and life plans sponsored by GE prior to the Spin-Off, including principal pension plans, other pension plans, and principal retiree benefit plans. A subset of these pension plans have been closed to new participants. For the three and nine months ended September 30, 2022, relevant participation costs for these plans were allocated to the Company and recognized within the Condensed Combined Statement of Income. These included service costs for active employees in the U.S. GE Pension Plan, certain international pension plans, the U.S. GE Supplementary Pension Plan, and the U.S. retiree benefit plan. We did not record any liabilities associated with our participation in these plans in our Condensed Combined Statement of Financial Position as of December 31, 2022.

Expenses associated with our employees’ participation in the U.S. GE principal pension and principal retiree benefit plans, which represent the majority of related expense, were $24 million and $73 million for the three and nine months ended September 30, 2022. Expenses associated with our employees’ participation in GE’s non-U.S. based pension plans were immaterial for the three and nine months ended September 30, 2022.

In connection with the Spin-Off, on January 1, 2023, these plans were separated and GE transferred certain liabilities and assets of these plans to GE HealthCare based upon measurements as of December 31, 2022. The amounts assumed by GE HealthCare on January 1, 2023, are shown in the tables below.


Accumulated Benefit Obligations and Unrecognized Gain
	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906

Unrecognized gain to be recorded in AOCI	1,258		1,223		2,481


Net Benefit Liability
	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of assets	18,908		—		18,908
Net liability	$	2,835	$	1,210	$	4,045

PENSION PLANS SPONSORED BY GE HEALTHCARE, INCLUDING THOSE TRANSFERRED BY GE.

As the pension plans were transferred by GE on January 1, 2023, there are no amounts included for these plans in the periods ended September 30, 2022. Pension plans with pension assets or obligations less than $50 million and $20 million as of September 30, 2023 and 2022, respectively, are not included in the results below.


Components of Expense (Income)
	For the three months ended September 30
	Defined benefit plans				Other postretirement plans

	2023		2022		2023		2022
Service cost – Operating	$	14	$	4	$	2	$	—
Interest cost	290		4		15		—
Expected return on plan assets	(357)		(7)		—		—
Amortization of net loss (gain)	(28)		2		(16)		—
Amortization of prior service cost (credit)	1		(1)		(22)		—
Curtailment loss (gain)	17		—		—		—
Non-operating	$	(77)	$	(2)	$	(23)	$	—
Net periodic expense (income)	$	(63)	$	2	$	(21)	$	—



	For the nine months ended September 30
	Defined benefit plans				Other postretirement plans

	2023		2022		2023		2022
Service cost – Operating	$	43	$	14	$	6	$	—
Interest cost	872		13		45		—
Expected return on plan assets	(1,070)		(21)		—		—
Amortization of net loss (gain)	(89)		5		(48)		—
Amortization of prior service cost (credit)	(1)		(3)		(66)		—
Curtailment loss (gain)	17		—		—		—
Non-operating	$	(271)	$	(6)	$	(69)	$	—
Net periodic expense (income)	$	(228)	$	8	$	(63)	$	—

In the third quarter of 2023, management approved an amendment to the U.S. based GE HealthCare Pension Plan whereby the benefits for all remaining active employees will be frozen effective December 31, 2024, and additional benefit enhancements were provided. As a result, we recognized a non-cash pre-tax curtailment loss of approximately $17 million as non-operating benefit costs and an increase to our pension liability of $23 million. As a result of the plan changes, we were required to remeasure the plan assets and the projected benefit obligation, these changes collectively decreased accumulated other comprehensive income (loss) by $305 million.

For the nine months ended September 30, 2023, the Company made contributions for benefit payments totaling $157 million to the pension plans and $102 million to its postretirement plans. During 2023, the Company expects to make total benefit payments of approximately $353 million to our defined benefit pension and postretirement plans for benefit payments. The Company does not have a required minimum cash pension contribution obligation for its U.S. plans in 2023. Future contributions will depend on market conditions, interest rates, and other factors.

Prior to the Spin-Off, we disclosed postretirement plans with assets or obligations that exceeded $20 million. As a result of the transferred liabilities and assets to GE HealthCare on January 1, 2023, we now present postretirement plans with assets or obligations that exceed $50 million. For the year, the Company expects to contribute approximately $11 million to postretirement plans that are no longer disclosed.

Defined Contribution Plan

As a result of the Spin-Off, GE HealthCare established a defined contribution plan for its eligible U.S. employees that was largely consistent with the plan they participated in while GE HealthCare operated as a business of GE. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan in 2023 and GE’s defined contribution plan in 2022 represent the employer matching contributions for GE HealthCare employees and were $28 million and $30 million for the three months ended September 30, 2023 and 2022, respectively, and $94 million and $96 million for the nine months ended September 30, 2023 and 2022, respectively.

- Definition

The entire disclosure for retirement benefits.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 70
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480794/715-70-50-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 17
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480482/715-20-55-17

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (q)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//715/tableOfContent

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(iii)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (o)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (p)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (r)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480506/715-20-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480126/715-20-S99-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 715
-SubTopic 60
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480266/715-60-50-3

+ Details

REVENUE RECOGNITION (Tables)

9 Months Ended

Sep. 30, 2023

Revenue from Contract with Customer [Abstract]

Summary of Contract and Other Deferred Assets


Contract and Other Deferred Assets
	As of
	September 30, 2023		December 31, 2022
Contract assets	$	650	$	584
Other deferred assets	388		405
Contract and other deferred assets	1,038		989
Non-current contract assets(1)	67		37
Non-current other deferred assets(1)	88		82
Total contract and other deferred assets	$	1,193	$	1,108

(1)Non-current contract and other deferred assets are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

EARNINGS PER SHARE - Schedule of Earnings per Share (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Numerator:
Net income from continuing operations	$ 386	$ 493	$ 1,202	$ 1,382
Net (income) loss attributable to noncontrolling interests	(7)	(6)	(33)	(32)
Net income from continuing operations attributable to GE HealthCare	379	487	1,169	1,350
Deemed preferred stock dividend of redeemable noncontrolling interest	0	0	(183)	0
Net income from continuing operations attributable to GE HealthCare common stockholders	379	487	986	1,350
Income (loss) from discontinued operations, net of taxes	(4)	0	(4)	12
Net income attributable to GE HealthCare common stockholders	$ 375	$ 487	$ 982	$ 1,362
Denominator:
Basic weighted-average shares outstanding	455	454	455	454
Dilutive effect of common stock equivalents (in shares)	3	0	3	0
Diluted weighted-average shares outstanding	458	454	458	454
Basic Earnings Per Share:
Continuing operations (in dollars per share)	$ 0.83	$ 1.07	$ 2.17	$ 2.97
Discontinued operations (in dollars per share)	(0.01)	0	(0.01)	0.03
Attributable to GE HealthCare common stockholders (in dollars per share)	0.82	1.07	2.16	3.00
Diluted Earnings Per Share:
Continuing operations (in dollars per share)	0.83	1.07	2.16	2.97
Discontinued operations (in dollars per share)	(0.01)	0	(0.01)	0.03
Attributable to GE HealthCare common stockholders (in dollars per share)	$ 0.82	$ 1.07	$ 2.15	$ 3.00
Antidilutive securities (in shares)	4	0	4	0

SUPPLEMENTAL FINANCIAL INFORMATION

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SUPPLEMENTAL FINANCIAL INFORMATION


Cash, Cash Equivalents and Restricted Cash	As of
	September 30, 2023		December 31, 2022
Cash and cash equivalents	$	2,408	$	1,440
Short-term restricted cash	10		5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	2,418		1,445
Long-term restricted cash(1)	2		6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$	2,420	$	1,451

(1) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.


Inventories
	As of
	September 30, 2023		December 31, 2022
Raw materials	$	989	$	1,053
Work in process	100		91
Finished goods	1,039		1,011
Inventories(1)	$	2,128	$	2,155

(1) Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.


Property, Plant, and Equipment – Net
	As of
	September 30, 2023		December 31, 2022
Original cost	$	5,011	$	4,989
Accumulated depreciation and amortization	(2,995)		(2,988)
Right-of-use operating lease assets	339		313
Property, plant, and equipment – net	$	2,355	$	2,314

ALL OTHER CURRENT AND NON-CURRENT ASSETS.

All other current assets primarily include prepaid expenses and deferred costs, derivative instruments, and financing receivables – net. All other non-current assets primarily include pension assets, equity method and other investments, financing receivables – net, contract and other deferred assets, inventories, and customer and sundry receivables – net. All other current and non-current assets increased in the nine months ended September 30, 2023, primarily due to assets transferred from GE as a result of the Spin-Off. Refer to Note 1, “Organization and Basis of Presentation” for further information.

ALL OTHER CURRENT AND NON-CURRENT LIABILITIES.

All other current liabilities primarily include employee compensation and benefits liabilities, sales allowances, equipment projects and other commercial liabilities, uncertain and other income tax payable, product warranties, interest payable, accrued freight and utilities, operating lease liabilities, and derivative instruments. All other non-current liabilities primarily include contract liabilities, operating lease liabilities, environmental, health and safety obligations, uncertain and other income tax payable, and derivative instruments. All other current and non-current liabilities increased in the nine months ended September 30, 2023, primarily due to liabilities transferred from GE as a result of the Spin-Off. Refer to Note 1, “Organization and Basis of Presentation” for further information.

SUPPLY CHAIN FINANCE PROGRAMS.

The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables as borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 150 days, not exceeding 180 days, depending on the underlying supplier agreements. Included in Accounts payable as of September 30, 2023 and December 31, 2022 were $396 million and $392 million, respectively, of confirmed supplier invoices that are outstanding and subject to the third-party programs.

REDEEMABLE NONCONTROLLING INTERESTS.

The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events, such as a change of control of the Company. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Condensed Consolidated and Combined Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable or probable of becoming redeemable are subsequently adjusted to the greater of current redemption value or initial carrying value. A change of control is generally not considered probable until it occurs.

The activity attributable to redeemable noncontrolling interests for the nine months ended September 30, 2023 and 2022 is presented below.


Redeemable Noncontrolling Interests
	For the nine months ended September 30
	2023		2022
Balance at beginning of period	$	230	$	220
Net income attributable to redeemable noncontrolling interests	28		24
Redemption value adjustments(1)	183		—
Distributions to and exercise of redeemable noncontrolling interests and other(2)	(280)		(46)
Balance at end of period	$	161	$	198

(1) As of January 3, 2023, certain redeemable noncontrolling interests were probable of becoming redeemable due to the change of control that occurred upon consummation of the Spin-Off. These redeemable noncontrolling interests were remeasured to their current redemption value resulting in a redemption value adjustment of $183 million. The remeasurement was accounted for as a deemed preferred stock dividend of redeemable noncontrolling interest and recorded as an adjustment to retained earnings.

(2) In the first quarter of 2023, the redeemable noncontrolling interest holder exercised its option redemption provision. The redemption amount of $211 million was paid in the second quarter of 2023.


Other Income (Expense) – Net
	For the three months ended September 30				For the nine months ended September 30
	2023		2022		2023		2022
Net interest and investment income (expense)	$	6	$	4	$	19	$	(8)
Equity method investment income	—		3		9		12
Change in fair value of assumed obligations	(5)		—		(24)		—
Other items, net(1)	62		11		81		59
Total other income (expense) – net	$	63	$	18	$	85	$	63

(1) Other items, net primarily consists of change in tax indemnity, lease income, gains and losses related to derivatives, and licensing and royalty income for the three and nine months ended September 30, 2023, and licensing and royalty income, and gains and losses related to derivatives for the three and nine months ended September 30, 2022.

RELATED PARTIES - Schedule of Related Party Transactions (Details) - Majority shareholder - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2022
Costs for centralized services
Related Party Transaction [Line Items]
Transaction amount	$ 12	$ 38
Costs associated with employee medical insurance
Related Party Transaction [Line Items]
Transaction amount	31	91
Costs for corporate and shared services
Related Party Transaction [Line Items]
Transaction amount	$ 123	$ 343

FINANCING RECEIVABLES - Schedule of Financing Receivable (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses, current	$ (3)	$ (4)
Current financing receivables, net	97	97
Allowance for credit losses, noncurrent	(4)	(6)
Non-current financing receivables, net	190	196
Loans, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	28	29
Non-current financing receivables, gross	38	44
Investment in financing leases, net of deferred income
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current financing receivables, gross	72	72
Non-current financing receivables, gross	$ 156	$ 158

SUPPLEMENTAL FINANCIAL INFORMATION (Tables)

9 Months Ended

Sep. 30, 2023

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Cash and Cash Equivalents


Cash, Cash Equivalents and Restricted Cash	As of
	September 30, 2023		December 31, 2022
Cash and cash equivalents	$	2,408	$	1,440
Short-term restricted cash	10		5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	2,418		1,445
Long-term restricted cash(1)	2		6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$	2,420	$	1,451

(1) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Schedule of Restricted Cash and Cash Equivalents


Cash, Cash Equivalents and Restricted Cash	As of
	September 30, 2023		December 31, 2022
Cash and cash equivalents	$	2,408	$	1,440
Short-term restricted cash	10		5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	2,418		1,445
Long-term restricted cash(1)	2		6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$	2,420	$	1,451

(1) Long-term restricted cash is recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Schedule of Inventory


Inventories
	As of
	September 30, 2023		December 31, 2022
Raw materials	$	989	$	1,053
Work in process	100		91
Finished goods	1,039		1,011
Inventories(1)	$	2,128	$	2,155

(1) Certain inventory items are long-term in nature and therefore have been recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

Summary of Property, Plant and Equipment


Property, Plant, and Equipment – Net
	As of
	September 30, 2023		December 31, 2022
Original cost	$	5,011	$	4,989
Accumulated depreciation and amortization	(2,995)		(2,988)
Right-of-use operating lease assets	339		313
Property, plant, and equipment – net	$	2,355	$	2,314

Schedule of Redeemable Noncontrolling Interest

The activity attributable to redeemable noncontrolling interests for the nine months ended September 30, 2023 and 2022 is presented below.


Redeemable Noncontrolling Interests
	For the nine months ended September 30
	2023		2022
Balance at beginning of period	$	230	$	220
Net income attributable to redeemable noncontrolling interests	28		24
Redemption value adjustments(1)	183		—
Distributions to and exercise of redeemable noncontrolling interests and other(2)	(280)		(46)
Balance at end of period	$	161	$	198

Schedule of Other Income (Expense)


Other Income (Expense) – Net
	For the three months ended September 30				For the nine months ended September 30
	2023		2022		2023		2022
Net interest and investment income (expense)	$	6	$	4	$	19	$	(8)
Equity method investment income	—		3		9		12
Change in fair value of assumed obligations	(5)		—		(24)		—
Other items, net(1)	62		11		81		59
Total other income (expense) – net	$	63	$	18	$	85	$	63

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Tables)

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

Schedule of Accumulated Other Comprehensive Income (Loss)

Changes in Accumulated other comprehensive income (loss) (“AOCI”) by component, net of income taxes, were as follows:


	For the three months ended September 30, 2023
	Currency translation adjustments(1)		Benefit plans		Cash flow hedges		Total AOCI
June 30, 2023	$	(1,757)	$	1,847	$	(20)	$	70
Other comprehensive income (loss) before reclasses – net of taxes of $(16), $69, and $(6)(4)	(143)		(214)		18		(339)

Reclasses from AOCI – net of taxes of $0, $16, and $(1)(3)	—		(50)		4		(46)


Other comprehensive income (loss)	(143)		(264)		22		(385)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(35)		—		—		(35)
September 30, 2023	$	(1,865)	$	1,583	$	2	$	(280)


	For the three months ended September 30, 2022
	Currency translation adjustments		Benefit plans		Cash flow hedges		Total AOCI
June 30, 2022	$	(1,594)	$	(102)	$	47	$	(1,649)
Other comprehensive income (loss) before reclasses – net of taxes of $8, $(3), and $(9)	(312)		9		22		(281)

Reclasses from AOCI – net of taxes of $0, $0, and $4(3)	—		1		(13)		(12)


Other comprehensive income (loss)	(312)		10		9		(293)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
September 30, 2022	$	(1,906)	$	(92)	$	56	$	(1,942)


	For the nine months ended September 30, 2023
	Currency translation adjustments(1)		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2022	$	(1,845)	$	(42)	$	9	$	(1,878)
Other comprehensive income (loss) before reclasses – net of taxes of $1, $60, and $(4)(4)	(84)		(190)		10		(264)
Reclasses from AOCI – net of taxes of $0, $49, and $5(3)	—		(156)		(17)		(173)
Other comprehensive income (loss)	(84)		(346)		(7)		(437)
Spin-Off related adjustments – net of taxes of $0, $(509), and $0(2)	28		1,972		—		2,000

Less: Other comprehensive income (loss) attributable to noncontrolling interests	(36)		1		—		(35)
September 30, 2023	$	(1,865)	$	1,583	$	2	$	(280)


	For the nine months ended September 30, 2022
	Currency translation adjustments		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2021	$	(969)	$	(100)	$	32	$	(1,037)
Other comprehensive income (loss) before reclasses – net of taxes of $(6), $(13), and $(11)	(937)		7		54		(876)

Reclasses from AOCI – net of taxes of $0, $0, and $4(3)	—		1		(30)		(29)


Other comprehensive income (loss)	(937)		8		24		(905)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
September 30, 2022	$	(1,906)	$	(92)	$	56	$	(1,942)

(1) The amount of foreign currency translation recognized in Other comprehensive income (loss) (“OCI”) during the nine months ended September 30, 2023 included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”

(2) Includes impact of $1,972 million to Benefit plans for unrecognized gain transferred from the GE pension and other postretirement plans and $28 million to Currency translation adjustments associated with other Spin-Off related adjustments. Refer to Note 9, “Postretirement Benefit Plans” for further information on the unrecognized gain transferred from the GE pension and other postretirement plans in connection with the Spin-Off.

(3) Reclassifications from AOCI into earnings for Benefit plans are recognized within Non-operating benefit (income) loss, while Cash flow hedges are recognized within Cost of products or Cost of services in our Condensed Consolidated and Combined Statements of Income.

(4) Includes pre-tax impact to Benefit plans of $(305) million for the pension plan amendment and related remeasurement of plan assets and benefit obligations. Refer to Note 9, “Postretirement Benefit Plans” for further information.

RECEIVABLES - Long-Term Receivables (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Receivables [Abstract]
Long-term customer receivables	$ 59	$ 80
Sundry receivables	79	57
Non-income based tax receivables	26	28
Supplier advances	9	11
Allowance for credit losses	(30)	(31)
Total long-term receivables – net	$ 143	$ 145

RELATED PARTIES

9 Months Ended

Sep. 30, 2023

RELATED PARTIES

PRIOR TO SPIN-OFF.

Prior to the Spin-Off, GE provided the Company with significant corporate infrastructure and shared services. Some of these services continue to be provided by GE to the Company on a temporary basis under the Transition Services Agreement, as discussed below. The following disclosures summarize related party activity between GE HealthCare and GE. This activity, which occurred prior to the Spin-Off, is included in the condensed combined financial statements.

Pensions, Benefit, and Contribution Plans

As discussed in Note 9, “Postretirement Benefit Plans”, employees of the Company participated in pensions, benefit, and contribution plans that were sponsored by GE. The Company was charged $59 million and $182 million for the three and nine months ended September 30, 2022 related to employee participation in these plans. In connection with the Spin-Off, a portion of these plans were transferred to the Company.

Share-based Compensation

GE granted various employee benefits to its group employees, including those of the Company, under the GE Long-Term Incentive Plan. These benefits primarily included stock options and restricted stock units. Compensation expense allocated to the Company was $19 million and $58 million for the three and nine months ended September 30, 2022, respectively, and is recognized within SG&A in the Condensed Combined Statement of Income.

Corporate Overhead and Other Allocations from GE

GE provided certain services described below that were charged to the Company based on employee headcount, revenue, or other allocation methodologies.


Corporate Allocations from GE	For the three months ended		For the nine months ended
	September 30, 2022		September 30, 2022
Costs for centralized services(1)	$	12	$	38
Costs associated with employee medical insurance(2)	31		91
Costs for corporate and shared services(3)	123		343

(1) Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Condensed Combined Statement of Income.

(2) Costs associated with employee medical insurance were recognized within Cost of products, Cost of services, SG&A, and R&D in the Condensed Combined Statement of Income based on the employee population.

(3) Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Condensed Combined Statement of Income.

Management believes that the expense and cost allocations have been determined on a basis that is a reasonable reflection of the utilization of services provided or the benefit received by the Company during the three and nine months ended September 30, 2022. The amounts that would have been, or will be incurred, on a stand-alone basis could materially differ from the amounts allocated due to economies of scale, difference in management judgment, a requirement for more or fewer employees, or other factors.

AFTER SPIN-OFF.

In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE, including, but not limited to the following which had activity during the first nine months of 2023:

•Separation and Distribution Agreement – sets forth the principal actions to be taken in connection with the Spin-Off, including the transfer of assets and assumption of liabilities, and establishes certain rights and obligations between the Company and GE following the Distribution, including procedures with respect to claims subject to indemnification and related matters.

•Transition Services Agreement – governs all matters relating to the provision of services between the Company and GE on a transitional basis. The services the Company receives include support for digital technology, human resources, supply chain, finance, and real estate services, among others. Some of these costs were included in the Corporate allocations from GE prior to Spin-Off. The services generally commenced on the date of the Spin-Off and will terminate up to 36 months following the Distribution Date depending upon the related transitional service. For the three and nine months ended September 30, 2023, we incurred $94 million and $286 million, net, which represents fees charged from GE to the Company primarily for information technology, human resources, and R&D and is net of fees charged from the Company to GE for facilities and other shared services.

•Tax Matters Agreement – governs the respective rights, responsibilities, and obligations between the Company and GE with respect to all tax matters (excluding employee-related taxes covered under the Employee Matters Agreement), in addition to certain restrictions which generally prohibit us from taking or failing to take any action in the two-year period following the Distribution that would prevent the Distribution from qualifying as tax-free for U.S. federal income tax purposes, including limitations on our ability to pursue certain strategic transactions. The TMA specifies the portion of tax liability for which the Company will bear contractual responsibility, and the Company and GE will each agree to indemnify each other against any amounts for which such indemnified party is not responsible. See Note 10, “Income Taxes” for further information on quarter to date and year to date TMA activity.

Current amounts due from and to GE under the various agreements described above are recognized within Due from related parties or Due to related parties, as applicable, in the Condensed Consolidated and Combined Statements of Financial Position. Non-current amounts due from GE were $82 million and due to GE were $28 million, and were recognized within All other assets or All other liabilities, as applicable, in the Condensed Consolidated Statement of Financial Position as of September 30, 2023. These amounts primarily relate to tax and other indemnities.

GE HealthCare sells products and services in the ordinary course of business to certain entities associated with two members of our Board of Directors. During the three and nine months ended September 30, 2023, we recognized revenue of $26 million and $73 million, respectively, from these entities in connection with providing products and services. Current amounts due from these entities as of September 30, 2023 were not significant.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-5

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-6

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(g)(3))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(c))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(2)(e))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//850/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-6

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 850
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483326/850-10-50-1

+ Details

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Cash, Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022	Sep. 30, 2022	Dec. 31, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Cash and cash equivalents	$ 2,408	$ 1,440
Short-term restricted cash	10	5
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Financial Position	2,418	1,445
Long-term restricted cash	2	6
Total cash, cash equivalents, and restricted cash as presented on the Condensed Consolidated and Combined Statements of Cash Flows	$ 2,420	$ 1,451	$ 504	$ 561

SEGMENT INFORMATION - Schedule of Segment Reporting Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Revenue	$ 4,822	$ 4,576	$ 14,346	$ 13,403
EBIT	744	700	2,119	2,017
Restructuring costs	(3)	(88)	(34)	(110)
Acquisition and disposition related benefits (charges)	14	49	15	20
Gain (loss) of business and asset dispositions	0	(2)	0	1
Spin-Off and separation costs	(45)	(7)	(175)	(7)
Amortization of acquisition-related intangible assets	(32)	(28)	(95)	(90)
Investment revaluation gain (loss)	2	(1)	1	(23)
Interest and other financial charges – net	(138)	(2)	(411)	(18)
Non-operating benefit income (costs)	94	1	332	4
Income from continuing operations before income taxes	636	622	1,752	1,794
Operating segments \| Imaging
Segment Reporting Information [Line Items]
Revenue	2,635	2,516	7,751	7,276
EBIT	318	267	787	779
Operating segments \| Imaging \| Radiology
Segment Reporting Information [Line Items]
Revenue	2,237	2,118	6,552	6,100
Operating segments \| Imaging \| Interventional Guidance
Segment Reporting Information [Line Items]
Revenue	398	398	1,199	1,176
Operating segments \| Ultrasound
Segment Reporting Information [Line Items]
Revenue	815	823	2,513	2,466
EBIT	179	211	577	623
Operating segments \| PCS
Segment Reporting Information [Line Items]
Revenue	764	701	2,315	2,130
EBIT	80	65	273	211
Operating segments \| PCS \| Monitoring Solutions
Segment Reporting Information [Line Items]
Revenue	573	506	1,688	1,539
Operating segments \| PCS \| Life Support Solutions
Segment Reporting Information [Line Items]
Revenue	191	195	627	591
Operating segments \| PDx
Segment Reporting Information [Line Items]
Revenue	589	522	1,715	1,485
EBIT	166	159	473	411
Other
Segment Reporting Information [Line Items]
Revenue	19	14	52	46
EBIT	$ 1	$ (2)	$ 9	$ (7)

EARNINGS PER SHARE - Narrative (Details) - shares	Sep. 30, 2023	Jan. 03, 2023	Dec. 31, 2022
Earnings Per Share [Abstract]
Common stock, outstanding (in shares)	455,224,438	454,000,000	100

ORGANIZATION AND BASIS OF PRESENTATION (Policies)	9 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION (Policies)	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION. The condensed consolidated and combined financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) and present the historical results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, cash flows for the nine months ended September 30, 2023 and 2022, and the financial position as of September 30, 2023 and December 31, 2022. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and operating results. The following tables are presented in millions of U.S dollars (“USD”) unless otherwise stated. Prior to the Spin-Off, the condensed combined financial statements were derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by GE. The condensed combined financial statements do not purport to reflect what the results of operations, comprehensive income (loss), financial position, or cash flows would have been had the Company operated as a separate, stand-alone entity prior to the Spin-Off. The condensed consolidated and combined financial statements should be read in conjunction with the Company’s audited combined financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022.
CONSOLIDATION	All intercompany balances and transactions within the Company have been eliminated in the condensed consolidated and combined financial statements.
ESTIMATES AND ASSUMPTIONS	ESTIMATES AND ASSUMPTIONS. The preparation of the condensed consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the condensed consolidated and combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. There have been no material impacts to our accounting estimates as of September 30, 2023 and December 31, 2022, or the results for the three and nine months ended September 30, 2023 and 2022, from the COVID-19 pandemic. The federal COVID-19 Public Health Emergency declaration in the U.S. ended in May 2023, and COVID-19 restrictions have been lifted in many locations globally.
ACCOUNTING CHANGES	ACCOUNTING CHANGES. Accounting Standards Codification (“ASC”) Topic 740, Income Taxes, provides that interest and penalties related to unrecognized income tax benefits may either be classified as income tax expense or interest expense in the condensed consolidated statements of operations. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions. The interest was previously presented within “Interest and other financial charges – net” and has changed to being presented within “Benefit (provision) for income taxes.” The Company believes this presentation is preferable because the cost is related to income tax matters and this presentation enhances comparability with our peers. The effects of the change in accounting have been prospectively applied to periods beginning in the first quarter of 2023 and were not material to any previously reported periods prior to March 31, 2023. Recent Accounting Pronouncements reflected in the Condensed Consolidated and Combined Financial Statements In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted this guidance on January 1, 2023. See Note 17, “Supplemental Financial Information” for further information. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and contract liabilities from contracts with customers on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance on January 1, 2023 using a prospective method, and the adoption did not have a material impact on the condensed consolidated financial statements.

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	$ 7,114	$ 17,054	$ 9,362	$ 16,676
Other comprehensive income (loss) before reclass – net of taxes	(339)	(281)	(264)	(876)
Reclass from AOCI – net of taxes	(46)	(12)	(173)	(29)
Other comprehensive income (loss)	(385)	(293)	(437)	(905)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(35)	0	(35)	0
Equity, ending balance	7,142	16,878	7,142	16,878
Defined benefit plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
AOCI, decrease due to remeasurement	305
Accumulated other comprehensive income (loss) – net
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	70	(1,649)	(1,878)	(1,037)
Spin-Off related adjustments – net of taxes			2,000
Equity, ending balance	(280)	(1,942)	(280)	(1,942)
Currency translation adjustments
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(1,757)	(1,594)	(1,845)	(969)
Other comprehensive income (loss) before reclass – net of taxes	(143)	(312)	(84)	(937)
Reclass from AOCI – net of taxes	0	0	0	0
Other comprehensive income (loss)	(143)	(312)	(84)	(937)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(35)	0	(36)	0
Spin-Off related adjustments – net of taxes			28
Equity, ending balance	(1,865)	(1,906)	(1,865)	(1,906)
Other comprehensive income (loss) before reclass, tax	(16)	8	1	(6)
Reclass from AOCI, tax	0	0	0	0
Spin-Off related adjustments, tax			0
Benefit plans
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	1,847	(102)	(42)	(100)
Other comprehensive income (loss) before reclass – net of taxes	(214)	9	(190)	7
Reclass from AOCI – net of taxes	(50)	1	(156)	1
Other comprehensive income (loss)	(264)	10	(346)	8
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	0	1	0
Spin-Off related adjustments – net of taxes			1,972
Equity, ending balance	1,583	(92)	1,583	(92)
Other comprehensive income (loss) before reclass, tax	69	(3)	60	(13)
Reclass from AOCI, tax	16	0	49	0
Spin-Off related adjustments, tax			(509)
Cash flow hedges
AOCI Including Portion Attributable to Noncontrolling Interest, Net of Tax [Roll Forward]
Equity, beginning balance	(20)	47	9	32
Other comprehensive income (loss) before reclass – net of taxes	18	22	10	54
Reclass from AOCI – net of taxes	4	(13)	(17)	(30)
Other comprehensive income (loss)	22	9	(7)	24
Less: Other comprehensive income (loss) attributable to noncontrolling interests	0	0	0	0
Spin-Off related adjustments – net of taxes			0
Equity, ending balance	2	56	2	56
Other comprehensive income (loss) before reclass, tax	(6)	(9)	(4)	(11)
Reclass from AOCI, tax	$ (1)	$ 4	5	$ 4
Spin-Off related adjustments, tax			$ 0

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Other Income (Expense) (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Net interest and investment income (expense)	$ 6	$ 4	$ 19	$ (8)
Equity method investment income	0	3	9	12
Change in fair value of assumed obligations	(5)	0	(24)	0
Other items, net	62	11	81	59
Total other income (expense) – net	$ 63	$ 18	$ 85	$ 63

SUPPLEMENTAL FINANCIAL INFORMATION - Narrative (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Supplier Finance Program [Line Items]
Supplier finance program, payment terms, maximum threshold	180 days
Supplier finance program obligation	$ 396	$ 392
Minimum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	30 days
Maximum
Supplier Finance Program [Line Items]
Supplier finance program, payment terms	150 days

FINANCING RECEIVABLES (Tables)

9 Months Ended

Sep. 30, 2023

Receivables [Abstract]

Schedule of Receivables


Current Receivables
	As of
	September 30, 2023		December 31, 2022
Current customer receivables(1)	$	3,189	$	3,112
Non-income based tax receivables	165		174
Other sundry receivables	110		100
Sundry receivables	275		274
Allowance for credit losses	(91)		(91)
Total current receivables – net	$	3,373	$	3,295


Long-Term Receivables
	As of
	September 30, 2023		December 31, 2022
Long-term customer receivables	$	59	$	80
Sundry receivables	79		57
Non-income based tax receivables	26		28
Supplier advances	9		11
Allowance for credit losses	(30)		(31)
Total long-term receivables – net(1)	$	143	$	145

(1) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.


Financing Receivables
	As of
	September 30, 2023		December 31, 2022
Loans, net of deferred income	$	28	$	29
Investment in financing leases, net of deferred income	72		72
Allowance for credit losses	(3)		(4)
Current financing receivables – net(1)	97		97
Loans, net of deferred income	38		44
Investment in financing leases, net of deferred income	156		158
Allowance for credit losses	(4)		(6)
Non-current financing receivables – net(1)	$	190	$	196

Pay vs Performance Disclosure - USD ($) $ in Millions	3 Months Ended		9 Months Ended
Pay vs Performance Disclosure - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Pay vs Performance Disclosure
Net income attributable to GE HealthCare	$ 375	$ 487	$ 1,165	$ 1,362

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

RESTRUCTURING AND OTHER ACTIVITIES - NET

9 Months Ended

Sep. 30, 2023

Restructuring and Related Activities [Abstract]

RESTRUCTURING AND OTHER ACTIVITIES - NET

RESTRUCTURING AND OTHER ACTIVITIES – NET

Restructuring activities are essential to optimize the business operating model for GE HealthCare as a stand-alone company and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring and other charges (gains) primarily include facility exit costs, employee-related termination benefits associated with workforce reductions, asset write-downs, and cease-use costs. For segment reporting, restructuring and other activities are not allocated.

As a result of committed restructuring initiatives, we recorded net expenses of $3 million and $88 million for the three months ended September 30, 2023 and 2022 and $34 million and $110 million for the nine months ended September 30, 2023 and 2022. These restructuring initiatives are expected to result in additional expenses of approximately $23 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and facility exit costs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or Selling, general, and administrative ("SG&A"), as appropriate, in the Condensed Consolidated and Combined Statements of Income.


Restructuring and Other Activities
	For the three months ended September 30				For the nine months ended September 30
	2023		2022		2023		2022
Employee termination costs	$	1	$	28	$	26	$	46
Facility and other exit costs	1		38		2		42
Asset write-downs	1		22		6		22
Total restructuring and other activities – net	$	3	$	88	$	34	$	110

In connection with the Spin-Off, GE transferred employee termination obligations for services already rendered of $31 million to GE HealthCare of which $5 million was remaining as of September 30, 2023. Liabilities related to restructuring are recognized within All other current liabilities and All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position and totaled $70 million and $75 million as of September 30, 2023 and December 31, 2022, respectively.

SUPPLEMENTAL FINANCIAL INFORMATION - Schedule of Inventory (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Raw materials	$ 989	$ 1,053
Work in process	100	91
Finished goods	1,039	1,011
Inventories	$ 2,128	$ 2,155

SUPPLEMENTAL FINANCIAL INFORMATION - Summary of Property, Plant and Equipment (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Original cost	$ 5,011	$ 4,989
Accumulated depreciation and amortization	(2,995)	(2,988)
Right-of-use operating lease assets	339	313
Property, plant, and equipment – net	$ 2,355	$ 2,314

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2023

Earnings Per Share [Abstract]

EARNINGS PER SHARE

On January 3, 2023, there were approximately 454 million shares of GE HealthCare common stock outstanding, including the interest in our outstanding shares of common stock retained by GE following the Distribution. The computation of basic and diluted earnings per common share for all periods through December 31, 2022, was calculated using this same number of common shares outstanding since no GE HealthCare equity awards were outstanding as of the Distribution Date and is net of Net (income) loss attributable to noncontrolling interest which is fully associated with continuing operations. Subsequent to the Spin-Off, the dilutive effect of outstanding stock options, RSUs, and PSUs are reflected in the denominator for diluted earnings per share using the treasury stock method.


Earnings Per Share
	For the three months ended September 30				For the nine months ended September 30
(In millions, except per share amounts)	2023		2022		2023		2022
Numerator:
Net income from continuing operations	$	386	$	493	$	1,202	$	1,382
Net (income) loss attributable to noncontrolling interests	(7)		(6)		(33)		(32)
Net income from continuing operations attributable to GE HealthCare	379		487		1,169		1,350
Deemed preferred stock dividend of redeemable noncontrolling interest	—		—		(183)		—
Net income from continuing operations attributable to GE HealthCare common stockholders	379		487		986		1,350
Income (loss) from discontinued operations, net of taxes	(4)		—		(4)		12
Net income attributable to GE HealthCare common stockholders	$	375	$	487	$	982	$	1,362
Denominator:
Basic weighted-average shares outstanding	455		454		455		454
Dilutive effect of common stock equivalents	3		—		3		—
Diluted weighted-average shares outstanding	458		454		458		454
Basic Earnings Per Share:
Continuing operations	$	0.83	$	1.07	$	2.17	$	2.97
Discontinued operations	(0.01)		—		(0.01)		0.03
Attributable to GE HealthCare common stockholders	0.82		1.07		2.16		3.00
Diluted Earnings Per Share:
Continuing operations	$	0.83	$	1.07	$	2.16	$	2.97
Discontinued operations	(0.01)		—		(0.01)		0.03
Attributable to GE HealthCare common stockholders	0.82		1.07		2.15		3.00
Antidilutive securities(1)	4		—		4		—

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

Condensed Consolidated and Combined Statements of Changes in Equity (Unaudited) - USD ($) $ in Millions	Total	Common stock	Additional paid-in capital	Retained earnings	Net parent investment	Accumulated other comprehensive income (loss) – net	Equity attributable to noncontrolling interests
Equity, beginning balance (in shares) at Dec. 31, 2021		0
Equity, beginning balance at Dec. 31, 2021	$ 16,676	$ 0	$ 0	$ 0	$ 17,692	$ (1,037)	$ 21
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to GE HealthCare	1,362				1,362
Other comprehensive income (loss) attributable to GE HealthCare	(905)					(905)
Transfers (to) from GE	(253)				(253)
Changes in equity attributable to noncontrolling interests	(2)						(2)
Equity, ending balance (in shares) at Sep. 30, 2022		0
Equity, ending balance at Sep. 30, 2022	16,878	$ 0	0	0	18,801	(1,942)	19
Equity, beginning balance (in shares) at Jun. 30, 2022		0
Equity, beginning balance at Jun. 30, 2022	17,054	$ 0	0	0	18,680	(1,649)	23
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income attributable to GE HealthCare	487				487
Other comprehensive income (loss) attributable to GE HealthCare	(293)					(293)
Transfers (to) from GE	(366)				(366)
Changes in equity attributable to noncontrolling interests	(4)						(4)
Equity, ending balance (in shares) at Sep. 30, 2022		0
Equity, ending balance at Sep. 30, 2022	$ 16,878	$ 0	0	0	18,801	(1,942)	19
Equity, beginning balance (in shares) at Dec. 31, 2022	100	0
Equity, beginning balance at Dec. 31, 2022	$ 9,362	$ 0	0	0	11,235	(1,878)	5
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net transfers from Parent, including Spin-Off-related adjustments	(2,840)				(4,842)	2,000	2
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment (in shares)		454,000,000
Issuance of common stock in connection with the Spin-Off and reclassification of net parent investment	0	$ 5	6,388		(6,393)
Issuance of common stock in connection with employee stock plans, net of shares withheld for employee taxes (in shares)		1,000,000
Net income attributable to GE HealthCare	1,165			1,165
Dividends declared	(41)			(41)
Other comprehensive income (loss) attributable to GE HealthCare	(402)					(402)
Changes in equity attributable to noncontrolling interests	4						4
Share-based compensation	81		81
Changes in equity due to redemption value adjustments on redeemable noncontrolling interests	$ (187)			(187)
Equity, ending balance (in shares) at Sep. 30, 2023	455,224,438	455,000,000
Equity, ending balance at Sep. 30, 2023	$ 7,142	$ 5	6,469	937	0	(280)	11
Equity, beginning balance (in shares) at Jun. 30, 2023		455,000,000
Equity, beginning balance at Jun. 30, 2023	7,114	$ 5	6,451	576	0	70	12
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock in connection with employee stock plans, net of shares withheld for employee taxes	(11)		(11)
Net income attributable to GE HealthCare	375			375
Dividends declared	(14)			(14)
Other comprehensive income (loss) attributable to GE HealthCare	(350)					(350)
Changes in equity attributable to noncontrolling interests	(1)						(1)
Share-based compensation	$ 29		29
Equity, ending balance (in shares) at Sep. 30, 2023	455,224,438	455,000,000
Equity, ending balance at Sep. 30, 2023	$ 7,142	$ 5	$ 6,469	$ 937	$ 0	$ (280)	$ 11

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Narrative (Details) $ in Millions	Sep. 30, 2023 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Guarantor obligations, maximum exposure	$ 114

Condensed Consolidated and Combined Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Statement of Comprehensive Income [Abstract]
Net income attributable to GE HealthCare	$ 375	$ 487	$ 1,165	$ 1,362
Net (income) loss attributable to noncontrolling interests	7	6	33	32
Net income	382	493	1,198	1,394
Other comprehensive income (loss):
Currency translation adjustments – net of taxes	(143)	(312)	(84)	(937)
Benefit plans – net of taxes	(264)	10	(346)	8
Cash flow hedges – net of taxes	22	9	(7)	24
Other comprehensive income (loss)	(385)	(293)	(437)	(905)
Comprehensive income (loss)	(3)	200	761	489
Less: Comprehensive income (loss) attributable to noncontrolling interests	(28)	6	(2)	32
Comprehensive income attributable to GE HealthCare	$ 25	$ 194	$ 763	$ 457

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

9 Months Ended

Sep. 30, 2023

Equity [Abstract]

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET

Changes in Accumulated other comprehensive income (loss) (“AOCI”) by component, net of income taxes, were as follows:


	For the three months ended September 30, 2023
	Currency translation adjustments(1)		Benefit plans		Cash flow hedges		Total AOCI
June 30, 2023	$	(1,757)	$	1,847	$	(20)	$	70
Other comprehensive income (loss) before reclasses – net of taxes of $(16), $69, and $(6)(4)	(143)		(214)		18		(339)

Reclasses from AOCI – net of taxes of $0, $16, and $(1)(3)	—		(50)		4		(46)


Other comprehensive income (loss)	(143)		(264)		22		(385)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(35)		—		—		(35)
September 30, 2023	$	(1,865)	$	1,583	$	2	$	(280)


	For the three months ended September 30, 2022
	Currency translation adjustments		Benefit plans		Cash flow hedges		Total AOCI
June 30, 2022	$	(1,594)	$	(102)	$	47	$	(1,649)
Other comprehensive income (loss) before reclasses – net of taxes of $8, $(3), and $(9)	(312)		9		22		(281)

Reclasses from AOCI – net of taxes of $0, $0, and $4(3)	—		1		(13)		(12)


Other comprehensive income (loss)	(312)		10		9		(293)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
September 30, 2022	$	(1,906)	$	(92)	$	56	$	(1,942)


	For the nine months ended September 30, 2023
	Currency translation adjustments(1)		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2022	$	(1,845)	$	(42)	$	9	$	(1,878)
Other comprehensive income (loss) before reclasses – net of taxes of $1, $60, and $(4)(4)	(84)		(190)		10		(264)
Reclasses from AOCI – net of taxes of $0, $49, and $5(3)	—		(156)		(17)		(173)
Other comprehensive income (loss)	(84)		(346)		(7)		(437)
Spin-Off related adjustments – net of taxes of $0, $(509), and $0(2)	28		1,972		—		2,000

Less: Other comprehensive income (loss) attributable to noncontrolling interests	(36)		1		—		(35)
September 30, 2023	$	(1,865)	$	1,583	$	2	$	(280)


	For the nine months ended September 30, 2022
	Currency translation adjustments		Benefit plans		Cash flow hedges		Total AOCI
December 31, 2021	$	(969)	$	(100)	$	32	$	(1,037)
Other comprehensive income (loss) before reclasses – net of taxes of $(6), $(13), and $(11)	(937)		7		54		(876)

Reclasses from AOCI – net of taxes of $0, $0, and $4(3)	—		1		(30)		(29)


Other comprehensive income (loss)	(937)		8		24		(905)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
September 30, 2022	$	(1,906)	$	(92)	$	56	$	(1,942)

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

On February 17, 2023, the Company acquired 100% of the stock of Caption Health, Inc. (“Caption Health”) for $127 million of upfront payment, $10 million future holdback payment, and potential earn-out payments valued at $13 million based primarily on various milestones and sales targets. The preliminary purchase price allocation resulted in goodwill of $94 million, intangible assets of $60 million, and deferred tax liabilities of $3 million. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business is non-deductible for tax purposes and is reported in the Ultrasound segment. Caption Health is an artificial intelligence (“AI”) company whose technology expands access to AI-guided ultrasound screening for novice users.

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about the fair value measurement of contingent consideration.


Goodwill
	Balance as of December 31, 2022		Acquisitions		Foreign exchange and other		Balance as of September 30, 2023
Imaging(1)	$	4,409	$	16	$	(3)	$	4,422
Ultrasound	3,835		94		(6)		3,923
PCS	2,036		—		—		2,036
PDx	2,533		—		—		2,533
Total Goodwill	$	12,813	$	110	$	(9)	$	12,914

(1) Includes the acquisition of IMACTIS SAS in the second quarter of 2023.

We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. We did not identify any reporting units that required an interim impairment test since the last annual impairment testing date.

Substantially all other intangible assets are subject to amortization. Intangible assets decreased during the nine months ended September 30, 2023, primarily as a result of amortization, partially offset by acquisitions in our Imaging and Ultrasound segments. Amortization expense was $89 million and $103 million for the three months ended September 30, 2023 and 2022, respectively, and $278 million and $307 million for the nine months ended September 30, 2023 and 2022, respectively.

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about the fair value measurement of contingent consideration.


Goodwill
	Balance as of December 31, 2022		Acquisitions		Foreign exchange and other		Balance as of September 30, 2023
Imaging(1)	$	4,409	$	16	$	(3)	$	4,422
Ultrasound	3,835		94		(6)		3,923
PCS	2,036		—		—		2,036
PDx	2,533		—		—		2,533
Total Goodwill	$	12,813	$	110	$	(9)	$	12,914

(1) Includes the acquisition of IMACTIS SAS in the second quarter of 2023.

Condensed Consolidated and Combined Statements of Income (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Revenue	$ 4,822	$ 4,576	$ 14,346	$ 13,403
Gross profit	1,935	1,773	5,766	5,247
Selling, general, and administrative	996	908	3,130	2,747
Research and development	322	260	890	755
Total operating expenses	1,318	1,168	4,020	3,502
Operating income	617	605	1,746	1,745
Interest and other financial charges – net	138	2	411	18
Non-operating benefit (income) costs	(94)	(1)	(332)	(4)
Other (income) expense – net	(63)	(18)	(85)	(63)
Income from continuing operations before income taxes	636	622	1,752	1,794
Benefit (provision) for income taxes	(250)	(129)	(550)	(412)
Net income from continuing operations	386	493	1,202	1,382
Income (loss) from discontinued operations, net of taxes	(4)	0	(4)	12
Net income	382	493	1,198	1,394
Net (income) loss attributable to noncontrolling interests	(7)	(6)	(33)	(32)
Net income attributable to GE HealthCare	375	487	1,165	1,362
Deemed preferred stock dividend of redeemable noncontrolling interest	0	0	(183)	0
Net income attributable to GE HealthCare common stockholders	$ 375	$ 487	$ 982	$ 1,362
Earnings per share from continuing operations attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	$ 0.83	$ 1.07	$ 2.17	$ 2.97
Diluted (in dollars per share)	0.83	1.07	2.16	2.97
Earnings per share attributable to GE HealthCare common stockholders:
Basic (in dollars per share)	0.82	1.07	2.16	3.00
Diluted (in dollars per share)	$ 0.82	$ 1.07	$ 2.15	$ 3.00
Weighted-average number of shares outstanding:
Basic (in shares)	455	454	455	454
Diluted (in shares)	458	454	458	454
Products
Revenue	$ 3,186	$ 3,012	$ 9,530	$ 8,702
Cost of revenue	2,076	1,995	6,197	5,825
Services
Revenue	1,636	1,564	4,816	4,701
Cost of revenue	$ 811	$ 808	$ 2,383	$ 2,331

RESTRUCTURING AND OTHER ACTIVITIES - NET - Narrative (Details) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
	Jan. 03, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Restructuring Cost and Reserve [Line Items]
Restructuring expenses, net		$ 3	$ 88	$ 34	$ 110
Expected restructuring expense remaining		23		23
Restructuring liabilities		70		70		$ 75
Spin-Off
Restructuring Cost and Reserve [Line Items]
Accrual adjustment	$ 31
Restructuring liabilities		$ 5		$ 5

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References + Details

RECEIVABLES - Current Receivables (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Accounts, Notes, Loans and Financing Receivable [Line Items]
Allowance for credit losses	$ (91)	$ (91)
Chargebacks	148	157
Nonrelated party
Accounts, Notes, Loans and Financing Receivable [Line Items]
Current customer receivables	3,189	3,112
Non-income based tax receivables	165	174
Other sundry receivables	110	100
Sundry receivables	275	274
Allowance for credit losses	(91)	(91)
Total current receivables – net	$ 3,373	$ 3,295

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS - Schedule of Goodwill (Details) $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($)
Goodwill [Roll Forward]
Beginning balance	$ 12,813
Acquisitions	110
Foreign exchange and other	(9)
Ending balance	12,914
Imaging
Goodwill [Roll Forward]
Beginning balance	4,409
Acquisitions	16
Foreign exchange and other	(3)
Ending balance	4,422
Ultrasound
Goodwill [Roll Forward]
Beginning balance	3,835
Acquisitions	94
Foreign exchange and other	(6)
Ending balance	3,923
PCS
Goodwill [Roll Forward]
Beginning balance	2,036
Acquisitions	0
Foreign exchange and other	0
Ending balance	2,036
PDx
Goodwill [Roll Forward]
Beginning balance	2,533
Acquisitions	0
Foreign exchange and other	0
Ending balance	$ 2,533

- Definition

Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.

+ References + Details

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Expense (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Share-based compensation expense (pre-tax)	$ 29	$ 81
Income tax benefits	(4)	(15)
Share-based compensation expense (after-tax)	$ 25	$ 66

REVENUE RECOGNITION - Summary of Contract and Other Deferred Assets (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Contract assets	$ 650	$ 584
Other deferred assets	388	405
Contract and other deferred assets	1,038	989
Non-current contract assets	67	37
Non-current other deferred assets	88	82
Total contract and other deferred assets	$ 1,193	$ 1,108

RECEIVABLES

9 Months Ended

Sep. 30, 2023

Receivables [Abstract]

RECEIVABLES


Current Receivables
	As of
	September 30, 2023		December 31, 2022
Current customer receivables(1)	$	3,189	$	3,112
Non-income based tax receivables	165		174
Other sundry receivables	110		100
Sundry receivables	275		274
Allowance for credit losses	(91)		(91)
Total current receivables – net	$	3,373	$	3,295


Long-Term Receivables
	As of
	September 30, 2023		December 31, 2022
Long-term customer receivables	$	59	$	80
Sundry receivables	79		57
Non-income based tax receivables	26		28
Supplier advances	9		11
Allowance for credit losses	(30)		(31)
Total long-term receivables – net(1)	$	143	$	145

(1) Long-term receivables are recognized within All other assets in the Condensed Consolidated and Combined Statements of Financial Position.

ORGANIZATION AND BASIS OF PRESENTATION	9 Months Ended
ORGANIZATION AND BASIS OF PRESENTATION	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
ORGANIZATION AND BASIS OF PRESENTATION	ORGANIZATION AND BASIS OF PRESENTATION BACKGROUND. GE HealthCare Technologies Inc. (“GE HealthCare,” the “Company,” “our,” or “we”) is a leading global medical technology, pharmaceutical diagnostics, and digital solutions innovator. We operate at the center of the healthcare ecosystem, helping enable precision care by increasing health system capacity, enhancing productivity, digitizing healthcare delivery, and improving clinical outcomes while serving patients’ demand for greater efficiency, access, and personalized medicine. Our products, services, and solutions are designed to enable clinicians to make more informed decisions quickly and efficiently, improving patient care from diagnosis to therapy to monitoring. On January 3, 2023 (the “Distribution Date”), the General Electric Company (“GE” or “Parent”) completed the previously announced spin-off of GE HealthCare Technologies Inc. (the “Spin-Off”). The Spin-Off was completed through a distribution of approximately 80.1% of the Company’s outstanding common stock to holders of record of GE's common stock as of the close of business on December 16, 2022 (the “Distribution”), which resulted in the issuance of approximately 454 million shares of common stock. Prior to the Distribution, the Company issued 100 shares of common stock in exchange for $1.00, all of which were held by GE as of December 31, 2022. As a result of the Distribution, the Company became an independent public company. Our common stock is listed under the symbol “GEHC” on the Nasdaq Stock Market LLC (“Nasdaq”). As of September 30, 2023, GE’s beneficial ownership was approximately 13.5% of the Company’s outstanding common stock. In connection with the Spin-Off, certain adjustments were recorded to reflect transfers from GE, the draw-down of the Term Loan Facility and settlement of Spin-Off transactions with GE, which resulted in the net reduction in Total equity of $2,840 million. These items substantially consisted of the transfer of: (1) certain pension plan liabilities and assets as described in Note 9, “Postretirement Benefit Plans,” (2) certain deferred income taxes as described in Note 10, “Income Taxes,” (3) deferred compensation liabilities of $548 million, and (4) employee termination obligations as described in Note 14, “Restructuring and Other Activities – Net.” In connection with the Spin-Off, the Company entered into or adopted several agreements that provide a framework for the relationship between the Company and GE. See Note 18, “Related Parties” for more information on these agreements. Unless the context otherwise requires, references to “GE HealthCare,” “we,” “us,” “our,” and the “Company” refer to (1) GE’s healthcare business prior to the Spin-Off as a carve-out business of GE with related condensed combined financial statements and (2) GE HealthCare Technologies Inc. and its subsidiaries following the Spin-Off with related condensed consolidated financial statements. BASIS OF PRESENTATION. The condensed consolidated and combined financial statements have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) and present the historical results of operations and comprehensive income (loss) for the three and nine months ended September 30, 2023 and 2022, cash flows for the nine months ended September 30, 2023 and 2022, and the financial position as of September 30, 2023 and December 31, 2022. It is management’s opinion that these financial statements include all normal and recurring adjustments necessary for a fair presentation of the Company’s financial position and operating results. The following tables are presented in millions of U.S dollars (“USD”) unless otherwise stated. All intercompany balances and transactions within the Company have been eliminated in the condensed consolidated and combined financial statements. These financial statements include certain transactions with GE, which are disclosed as related party transactions. See Note 18, “Related Parties” for further information. Prior to the Spin-Off, the condensed combined financial statements were derived from the consolidated financial statements and accounting records of GE including the historical cost basis of assets and liabilities comprising the Company, as well as the historical revenues, direct costs, and allocations of indirect costs attributable to the operations of the Company, using the historical accounting policies applied by GE. The condensed combined financial statements do not purport to reflect what the results of operations, comprehensive income (loss), financial position, or cash flows would have been had the Company operated as a separate, stand-alone entity prior to the Spin-Off. The condensed consolidated and combined financial statements should be read in conjunction with the Company’s audited combined financial statements and notes included in our Annual Report on Form 10-K for the year ended December 31, 2022. ESTIMATES AND ASSUMPTIONS. The preparation of the condensed consolidated and combined financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the condensed consolidated and combined financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows. There have been no material impacts to our accounting estimates as of September 30, 2023 and December 31, 2022, or the results for the three and nine months ended September 30, 2023 and 2022, from the COVID-19 pandemic. The federal COVID-19 Public Health Emergency declaration in the U.S. ended in May 2023, and COVID-19 restrictions have been lifted in many locations globally. ACCOUNTING CHANGES. Accounting Standards Codification (“ASC”) Topic 740, Income Taxes, provides that interest and penalties related to unrecognized income tax benefits may either be classified as income tax expense or interest expense in the condensed consolidated statements of operations. In the first quarter of 2023, the Company changed its accounting policy for presentation of interest expense on uncertain tax positions. The interest was previously presented within “Interest and other financial charges – net” and has changed to being presented within “Benefit (provision) for income taxes.” The Company believes this presentation is preferable because the cost is related to income tax matters and this presentation enhances comparability with our peers. The effects of the change in accounting have been prospectively applied to periods beginning in the first quarter of 2023 and were not material to any previously reported periods prior to March 31, 2023. Recent Accounting Pronouncements reflected in the Condensed Consolidated and Combined Financial Statements In September 2022, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2022-04, Liabilities – Supplier Finance Programs (Subtopic 405-50). The ASU requires companies to disclose information about supplier finance programs, including key terms of the program, outstanding confirmed amounts as of the end of the period, a rollforward of such amounts during each annual period, and a description of where the amounts are presented. The new standard does not affect the recognition, measurement, or financial statement presentation of supplier finance obligations. The ASU is effective for fiscal years beginning after December 15, 2022, including interim periods, except for rollforward information, which is effective for fiscal years beginning after December 15, 2023. The Company adopted this guidance on January 1, 2023. See Note 17, “Supplemental Financial Information” for further information. In October 2021, the FASB issued ASU No. 2021-08, Business Combinations (Topic 805): Accounting for Contract Assets and Contract Liabilities from Contracts with Customers. The ASU requires companies to apply the definition of a performance obligation under ASC 606, Revenue from Contracts with Customers, to recognize and measure contract assets and contract liabilities relating to contracts with customers acquired in a business combination. Prior to the adoption of this ASU, an acquirer generally recognized assets acquired and liabilities assumed in a business combination, including contract assets and contract liabilities arising from revenue contracts with customers, at fair value on the acquisition date. The ASU results in the acquirer recording acquired contract assets and contract liabilities from contracts with customers on the same basis that would have been recorded by the acquiree before the acquisition under ASC 606. The ASU is effective for fiscal years beginning after December 15, 2022, with early adoption permitted. The Company adopted this guidance on January 1, 2023 using a prospective method, and the adoption did not have a material impact on the condensed consolidated financial statements.

SHARE-BASED COMPENSATION - Summary of Share-Based Compensation Activity (Details) $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended
	Sep. 30, 2023 USD ($) $ / shares shares	Sep. 30, 2023 USD ($) $ / shares shares
Stock options, shares
Outstanding at beginning of period (in shares) \| shares	3,738
Granted (in shares) \| shares	2,156
Exercised (in shares) \| shares	(524)
Forfeited (in shares) \| shares	(128)
Expired (in shares) \| shares	(200)
Outstanding at end of period (in shares) \| shares	5,042	5,042
Exercisable (in shares) \| shares	2,852	2,852
Expected to vest (in shares) \| shares	1,721	1,721
Stock options, weighted average exercise price
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 90
Granted (in dollars per share) \| $ / shares	72
Exercised (in dollars per share) \| $ / shares	60
Forfeited (in dollars per share) \| $ / shares	71
Expired (in dollars per share) \| $ / shares	127
Outstanding at end of period (in dollars per share) \| $ / shares	84	$ 84
Exercisable (in dollars per share) \| $ / shares	93	93
Expected to vest (in dollars per share) \| $ / shares	$ 72	$ 72
Stock options, weighted average contractual term (in years)
Stock options, weighted average remaining contractual term, outstanding	6 years 3 months 18 days
Stock options, weighted average remaining contractual term, exercisable	4 years 1 month 6 days
Stock options, weighted average remaining contractual term, expected to vest	9 years 3 months 18 days
Stock options, intrinsic value
Stock options, intrinsic value, outstanding \| $	$ 14	$ 14
Stock options, intrinsic value, exercisable \| $	14	14
Stock options, intrinsic value, expected to vest \| $	$ 0	$ 0
RSUs
RSUs, shares
Outstanding at beginning of period (in shares) \| shares	3,551
Granted (in shares) \| shares	1,860
Vested (in shares) \| shares	(1,201)
Forfeited (in shares) \| shares	(270)
Outstanding at end of period (in shares) \| shares	3,940	3,940
Expected to vest (in shares) \| shares	3,363	3,363
RSUs, weighted average grant date fair value
Outstanding at beginning of period (in dollars per share) \| $ / shares	$ 58
Granted (in dollars per share) \| $ / shares	73	$ 73
Vested (in dollars per share) \| $ / shares	56
Forfeited (in dollars per share) \| $ / shares	65
Outstanding at end of period (in dollars per share) \| $ / shares	66	66
Expected to vest (in dollars per share) \| $ / shares	$ 59	$ 59
RSUs, weighted average contractual term (in years)
Weighted average remaining contractual term, outstanding	1 year 8 months 12 days
Weighted average remaining contractual term, expected to vest	1 year 8 months 12 days
RSUs, intrinsic value
Intrinsic value, outstanding \| $	$ 268	$ 268
Intrinsic value, expected to vest \| $	$ 229	$ 229

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

9 Months Ended

Sep. 30, 2023

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

GUARANTEES.

The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings” for further information. In addition, prior to Spin-Off GE had provided performance guarantees in certain jurisdictions where we lacked the legal structure to issue the requisite guarantees required on certain projects.

Following the Spin-Off, which was completed pursuant to a Separation and Distribution Agreement (the "Separation and Distribution Agreement"), the Company has remaining performance guarantees on behalf of GE. Under the Separation and Distribution Agreement, GE is obligated to use reasonable best efforts to replace the Company as the guarantor or terminate all such performance guarantees. Until such termination or replacement, in the event of non-fulfillment of contractual obligations by the relevant obligors, the Company could be obligated to make payments under the applicable instruments for which GE is obligated to reimburse and indemnify the Company. As of September 30, 2023 the Company’s maximum aggregate exposure, subject to GE reimbursement, is approximately $114 million.

PRODUCT WARRANTIES.

We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows.


Product Warranties
	For the nine months ended September 30
	2023		2022
Balance at beginning of period	$	193	$	161
Current-year provisions	158		182
Expenditures	(159)		(151)
Other changes	(3)		(12)
Balance at end of period	$	189	$	180

Product warranties are recognized within All other current liabilities in the Condensed Consolidated and Combined Statements of Financial Position.

LEGAL MATTERS.

In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matters described below that could have a material impact on our results of operations and cash flows. In many proceedings, including the specific matters described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated.

Contracts with Iraqi Ministry of Health

In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all of the judges on the U.S. Court of Appeals for the District of Columbia Circuit (the “D.C. Circuit”). In February 2023, the D.C. Circuit denied this request. Also in February 2023, defendants filed a motion for a temporary, partial stay of further district court proceedings until the Supreme Court issues its decision in a separate case, Twitter, Inc. v. Taamneh, which also involves the U.S. Anti-Terrorism Act. In March 2023, the District Court granted the motion for a temporary, partial stay. In May 2023, the Supreme Court issued its opinion in Twitter, Inc. v. Taamneh, and the stay currently remains in effect. In June 2023, defendants petitioned the Supreme Court to review the D.C. Circuit’s decision. On October 2, 2023, the Supreme Court invited the Solicitor General to file a brief in this case expressing the views of the United States.

Government Disclosures

From time to time, we make self-disclosures regarding our compliance with the Foreign Corrupt Practices Act (“FCPA”) and similar laws to relevant authorities who may pursue or decline to pursue enforcement proceedings against us. We, with the assistance of outside counsel, made voluntarily self-disclosures to the U.S. Securities and Exchange Commission (“SEC”) and the U.S. Department of Justice (“DOJ”) beginning in 2018 regarding tender irregularities and other potential violations of the FCPA relating to our activities in certain provinces in China. We have been engaged in ongoing discussions with each of the SEC and the DOJ regarding these matters. We are fully cooperating with the reviews by these agencies and have implemented, and continue to implement, enhancements to our compliance policies and practices. At this time, we are unable to predict the duration, scope, result, or related costs associated with these disclosures to the SEC and the DOJ. We also are unable to predict what, if any, action may be taken by the SEC or the DOJ or what penalties or remedial actions they may seek. Any determination that our operations or activities are not in compliance with existing laws or regulations, including applicable foreign laws, could result in the imposition of fines, penalties, disgorgement, equitable relief, or other losses.

RELATED PARTIES (Tables)

9 Months Ended

Sep. 30, 2023

Schedule of Related Party Transactions


Corporate Allocations from GE	For the three months ended		For the nine months ended
	September 30, 2022		September 30, 2022
Costs for centralized services(1)	$	12	$	38
Costs associated with employee medical insurance(2)	31		91
Costs for corporate and shared services(3)	123		343

(1) Costs for centralized services such as public relations, treasury and cash management, and other services were recognized within SG&A in the Condensed Combined Statement of Income.

(3) Costs for corporate and shared services such as information technology, finance and other services were primarily recognized in SG&A and R&D in the Condensed Combined Statement of Income.

REVENUE RECOGNITION - Narrative (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Contract liabilities	$ 2,610		$ 2,526
Contract liabilities, noncurrent	683		$ 630
Increase in contract liabilities due to customer advances	84
Contract liabilities, revenue recognized	1,357	$ 1,377
Remaining performance obligation, amount	14,162
Products
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 4,865
Products \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	99.00%
Remaining performance obligation, period	2 years
Services
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, amount	$ 9,297
Services \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 \| Period one
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	65.00%
Remaining performance obligation, period	2 years
Services \| Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-10-01 \| Period two
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Remaining performance obligation, percentage	94.00%
Remaining performance obligation, period	5 years

RESTRUCTURING AND OTHER ACTIVITIES - NET - Schedule of Restructuring and Related Costs (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Restructuring and Related Activities [Abstract]
Employee termination costs	$ 1	$ 28	$ 26	$ 46
Facility and other exit costs	1	38	2	42
Asset write-downs	1	22	6	22
Total restructuring and other activities – net	$ 3	$ 88	$ 34	$ 110

Condensed Consolidated and Combined Statements of Changes in Equity (Unaudited) (Parenthetical) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2023
Statement of Stockholders' Equity [Abstract]
Dividends declared per common share (in dollars per share)	$ 0.03	$ 0.09

SEGMENT INFORMATION (Tables)

9 Months Ended

Sep. 30, 2023

Segment Reporting [Abstract]

Schedule of Segment Reporting Information


Total Revenues by Segment
	For the three months ended September 30				For the nine months ended September 30

	2023		2022		2023		2022
Imaging:
Radiology	$	2,237	$	2,118	$	6,552	$	6,100
Interventional Guidance	398		398		1,199		1,176
Total Imaging	2,635		2,516		7,751		7,276
Total Ultrasound	815		823		2,513		2,466
PCS:
Monitoring Solutions	573		506		1,688		1,539
Life Support Solutions	191		195		627		591
Total PCS	764		701		2,315		2,130
Total PDx	589		522		1,715		1,485
Other(1)	19		14		52		46
Total revenues	$	4,822	$	4,576	$	14,346	$	13,403


Segment EBIT
	For the three months ended September 30				For the nine months ended September 30
	2023		2022		2023		2022
Segment EBIT
Imaging	$	318	$	267	$	787	$	779
Ultrasound	179		211		577		623
PCS	80		65		273		211
PDx	166		159		473		411
Other(1)	1		(2)		9		(7)
	744		700		2,119		2,017
Restructuring costs	(3)		(88)		(34)		(110)
Acquisition and disposition related benefits (charges)	14		49		15		20
Gain (loss) of business and asset dispositions	—		(2)		—		1
Spin-Off and separation costs	(45)		(7)		(175)		(7)
Amortization of acquisition-related intangible assets	(32)		(28)		(95)		(90)
Investment revaluation gain (loss)	2		(1)		1		(23)
Interest and other financial charges – net	(138)		(2)		(411)		(18)
Non-operating benefit income (costs)	94		1		332		4
Income from continuing operations before income taxes	$	636	$	622	$	1,752	$	1,794

POSTRETIREMENT BENEFIT PLANS - Components of Net Periodic Expense (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Defined Benefit Plan Disclosure [Line Items]
Non-operating	$ (94)	$ (1)	$ (332)	$ (4)
Defined benefit plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	14	4	43	14
Interest cost	290	4	872	13
Expected return on plan assets	(357)	(7)	(1,070)	(21)
Amortization of net loss (gain)	(28)	2	(89)	5
Amortization of prior service cost (credit)	1	(1)	(1)	(3)
Curtailment loss (gain)	17	0	17	0
Non-operating	(77)	(2)	(271)	(6)
Net periodic expense (income)	(63)	2	(228)	8
Other postretirement plans
Defined Benefit Plan Disclosure [Line Items]
Service cost – Operating	2	0	6	0
Interest cost	15	0	45	0
Expected return on plan assets	0	0	0	0
Amortization of net loss (gain)	(16)	0	(48)	0
Amortization of prior service cost (credit)	(22)	0	(66)	0
Curtailment loss (gain)	0	0	0	0
Non-operating	(23)	0	(69)	0
Net periodic expense (income)	$ (21)	$ 0	$ (63)	$ 0

BORROWINGS - Schedule of Long-Term Borrowings (Details) - USD ($) $ in Millions	Sep. 30, 2023	Dec. 31, 2022
Debt Instrument [Line Items]
Principal debt issued	$ 10,301	$ 8,288
Less: Unamortized debt issuance costs and discounts	41	47
Less: Current portion of long-term borrowings	7	7
Long-term borrowings, net of current portion	$ 10,253	8,234
Senior notes \| 5.550% senior notes due November 15, 2024
Debt Instrument [Line Items]
Stated interest rate	5.55%
Principal debt issued	$ 1,000	1,000
Senior notes \| 5.600% senior notes due November 15, 2025
Debt Instrument [Line Items]
Stated interest rate	5.60%
Principal debt issued	$ 1,500	1,500
Senior notes \| 5.650% senior notes due November 15, 2027
Debt Instrument [Line Items]
Stated interest rate	5.65%
Principal debt issued	$ 1,750	1,750
Senior notes \| 5.857% senior notes due March 15, 2030
Debt Instrument [Line Items]
Stated interest rate	5.857%
Principal debt issued	$ 1,250	1,250
Senior notes \| 5.905% senior notes due November 22, 2032
Debt Instrument [Line Items]
Stated interest rate	5.905%
Principal debt issued	$ 1,750	1,750
Senior notes \| 6.377% senior notes due November 22, 2052
Debt Instrument [Line Items]
Stated interest rate	6.377%
Principal debt issued	$ 1,000	1,000
Line of credit \| Floating rate Term Loan Facility
Debt Instrument [Line Items]
Principal debt issued	2,000	0
Other
Debt Instrument [Line Items]
Principal debt issued	$ 51	$ 38

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivatives is to reduce the earnings and cash flow volatility associated with fluctuations in foreign currency exchange rates, equity prices, and commodity prices and hedge the volatility associated with the translation of the assets and liabilities of subsidiaries with a different functional currency than USD. These hedge contracts reduce, but do not entirely eliminate, the impact of foreign currency rate, equity price, and commodity price movements. The Company does not enter into or hold derivative instruments for speculative trading purposes.

Cash Flow Hedges

The total amount in AOCI related to cash flow hedges of foreign currency-denominated forecasted transactions was a $2 million gain, net of taxes, as of September 30, 2023. We expect to reclassify $10 million of pre-tax net deferred gains associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the earnings effects of the related forecasted transactions. Pre-tax gains (losses) reclassified from AOCI into earnings were $(5) million and $17 million, for the three months ended September 30, 2023 and 2022, respectively, and $22 million and $34 million for the nine months ended September 30, 2023 and 2022, respectively. As of September 30, 2023, the maximum length of time over which we are hedging our forecasted transactions was approximately two years.

Net Investment Hedges

The Company uses derivative instruments to hedge the currency risk associated with its net investment in foreign operations. The derivative instruments include cross-currency swaps and foreign currency forward contracts in combination with foreign currency option contracts. As of September 30, 2023, the Company had $3,093 million gross notional of derivatives consisting mainly of $2,126 million receive-fixed USD, pay-fixed Euro (“EUR”) cross-currency swaps and $871 million notional Chinese renminbi-denominated foreign currency forward and options contracts. The Company entered into each of the forward contracts concurrently with two separate foreign currency option contracts for the same notional amounts and expiration dates as the forward contracts. These instruments were each designated as the hedging instruments in net investment hedging relationships in order to mitigate the foreign currency risk attributable to the translation of its net investment in certain EUR-functional and Chinese renminbi-functional subsidiaries.

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:


Fair Value of Derivatives
	September 30, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,113	$	41	$	35	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,113		41		35		1,240		32		53
Cross-currency swaps	2,126		22		141		2,132		—		111
Foreign currency exchange contracts and options	967		10		9		—		—		—
Derivatives accounted for as net investment hedges	3,093		32		150		2,132		—		111
Foreign currency exchange contracts	4,436		13		29		4,456		9		20
Other derivatives(1)	441		40		1		660		25		25



Derivatives not designated as hedging instruments	4,877		53		30		5,116		34		45
Total derivatives	$	9,083	$	126	$	215	$	8,488	$	66	$	209

(1) Other derivatives are comprised of embedded derivatives, equity contracts, and commodity derivatives.

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis on our Condensed Consolidated and Combined Statements of Financial Position and in the table above. The fair value of the derivatives contracts is recognized within All other current assets, All other assets, All other current liabilities, and All other liabilities in the Condensed Consolidated and Combined Statements of Financial Position based upon the contractual timing of settlements for these contracts.

As of September 30, 2023, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $56 million.

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the three months ended September 30				For the nine months ended September 30
	2023		2022		2023		2022
Cash flow hedges	$	24	$	31	$	14	$	65
Net investment hedges	64		—		(7)		—

The tables below present the gains (losses) of our derivative financial instruments in the Condensed Consolidated and Combined Statements of Income.


Derivative Financial Instruments
	For the three months ended September 30, 2023								For the three months ended September 30, 2022
	Cost of products		Cost of services		Selling, general and administrative		Other(2)		Cost of products		Cost of services		Selling, general and administrative		Other(2)

Foreign currency exchange contracts	$	(5)	$	(1)	$	—	$	—	$	13	$	4	$	—	$	—
Effects of cash flow hedges	(5)		(1)		—		—		13		4		—		—

Foreign currency exchange contracts and options	—		—		—		1		—		—		—		—
Effects of net investment hedges	—		—		—		1		—		—		—		—
Foreign currency exchange contracts	(38)		(9)		—		4		(25)		(5)		—		5



Other derivatives(1)	—		—		(2)		10		—		—		—		7
Effects of derivatives not designated as hedging instruments	$	(38)	$	(9)	$	(2)	$	14	$	(25)	$	(5)	$	—	$	12


	For the nine months ended September 30, 2023								For the nine months ended September 30, 2022
	Cost of products		Cost of services		Selling, general and administrative		Other(2)		Cost of products		Cost of services		Selling, general and administrative		Other(2)

Foreign currency exchange contracts	$	18	$	4	$	—	$	—	$	27	$	7	$	—	$	—
Effects of cash flow hedges	18		4		—		—		27		7		—		—

Foreign currency exchange contracts and options	—		—		—		1		—		—		—		—
Effects of net investment hedges	—		—		—		1		—		—		—		—
Foreign currency exchange contracts	(28)		(6)		—		10		(86)		(16)		—		12



Other derivatives(1)	—		—		5		36		—		—		—		29
Effects of derivatives not designated as hedging instruments	$	(28)	$	(6)	$	5	$	46	$	(86)	$	(16)	$	—	$	41

(1) Other derivatives are comprised of embedded derivatives, equity contracts, and commodity derivatives.

(2) Amounts inclusive of Other income (expense) – net and Interest and other financial charges – net on the Condensed Consolidated and Combined Statements of Income.

FAIR VALUE MEASUREMENTS.

The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Financial Assets and Liabilities
	As of September 30, 2023								As of December 31, 2022
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Investment securities	$	28	$	—	$	—	$	28	$	21	$	—	$	—	$	21
Derivatives	—		126		—		126		—		66		—		66
Liabilities:
Deferred compensation(1)	236		3		—		239		62		2		—		64
Derivatives	—		215		—		215		—		203		6		209
Contingent consideration	—		—		49		49		—		—		42		42

(1) Certain deferred compensation plans whose value is derived from market-based securities values were transferred from GE as part of the Spin-Off.

Contingent Consideration

The contingent consideration liabilities as of September 30, 2023 and December 31, 2022 were recorded in connection with business acquisitions. Changes in the Level 3 fair value measurement of contingent consideration were not material during the nine months ended September 30, 2023.

Fair Value of Other Financial Instruments

The estimated fair value of long-term debt (including the current portion) as of September 30, 2023 and December 31, 2022 was $10,465 million and $8,512 million compared to a carrying value (which includes a reduction for amortized debt issuance costs and discounts) of $10,260 million and $8,241 million, respectively. The fair value of our borrowings is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” for further information.

Non-recurring Fair Value Measurements

Equity investments without readily determinable fair value as of September 30, 2023 and December 31, 2022 were $129 million and $117 million, respectively.

BORROWINGS - Narrative (Details)		9 Months Ended
BORROWINGS - Narrative (Details)	Jan. 03, 2023 USD ($)	Sep. 30, 2023 USD ($) series	Dec. 31, 2022 USD ($)
Debt Instrument [Line Items]
Weighted average interest rate		6.01%
Debt repayments		$ 0
Guarantor obligations, maximum exposure		114,000,000
Guarantee obligation, carrying value		4,000,000	$ 4,000,000
Commercial contracts
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		724,000,000	657,000,000
Equipment residual value obligation
Debt Instrument [Line Items]
Guarantor obligations, maximum exposure		39,000,000	43,000,000
Senior notes \| Senior unsecured notes
Debt Instrument [Line Items]
Debt, principal amount		$ 8,250,000,000
Number of debt series \| series		6
Line of credit \| Revolving credit facility
Debt Instrument [Line Items]
Line of credit outstanding		$ 0	$ 0
Line of credit \| Revolving credit facility \| 5-Year Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term		5 years
Maximum borrowing capacity		$ 2,500,000,000
Line of credit \| Revolving credit facility \| 364-Day Revolving Credit Facility
Debt Instrument [Line Items]
Debt, term		364 days
Maximum borrowing capacity		$ 1,000,000,000
Line of credit \| Unsecured debt \| Floating rate Term Loan Facility
Debt Instrument [Line Items]
Debt, term		3 years
Maximum borrowing capacity		$ 2,000,000,000
Proceeds from lines of credit	$ 2,000,000,000

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS (Tables)

9 Months Ended

Sep. 30, 2023

Fair Value Disclosures [Abstract]

Schedule of Derivative Assets at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:


Fair Value of Derivatives
	September 30, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,113	$	41	$	35	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,113		41		35		1,240		32		53
Cross-currency swaps	2,126		22		141		2,132		—		111
Foreign currency exchange contracts and options	967		10		9		—		—		—
Derivatives accounted for as net investment hedges	3,093		32		150		2,132		—		111
Foreign currency exchange contracts	4,436		13		29		4,456		9		20
Other derivatives(1)	441		40		1		660		25		25



Derivatives not designated as hedging instruments	4,877		53		30		5,116		34		45
Total derivatives	$	9,083	$	126	$	215	$	8,488	$	66	$	209

(1) Other derivatives are comprised of embedded derivatives, equity contracts, and commodity derivatives.

Schedule of Derivative Liabilities at Fair Value

The following table presents the gross fair values of our outstanding derivative instruments as of the dates indicated:


Fair Value of Derivatives
	September 30, 2023						December 31, 2022
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency exchange contracts	$	1,113	$	41	$	35	$	1,240	$	32	$	53
Derivatives accounted for as cash flow hedges	1,113		41		35		1,240		32		53
Cross-currency swaps	2,126		22		141		2,132		—		111
Foreign currency exchange contracts and options	967		10		9		—		—		—
Derivatives accounted for as net investment hedges	3,093		32		150		2,132		—		111
Foreign currency exchange contracts	4,436		13		29		4,456		9		20
Other derivatives(1)	441		40		1		660		25		25



Derivatives not designated as hedging instruments	4,877		53		30		5,116		34		45
Total derivatives	$	9,083	$	126	$	215	$	8,488	$	66	$	209

(1) Other derivatives are comprised of embedded derivatives, equity contracts, and commodity derivatives.

Schedule of Derivative Pre-tax Gains (Losses) Recognized in OCI

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the three months ended September 30				For the nine months ended September 30
	2023		2022		2023		2022
Cash flow hedges	$	24	$	31	$	14	$	65
Net investment hedges	64		—		(7)		—

Effect of Derivatives Instruments on Statements of Income

The tables below present the gains (losses) of our derivative financial instruments in the Condensed Consolidated and Combined Statements of Income.


Derivative Financial Instruments
	For the three months ended September 30, 2023								For the three months ended September 30, 2022
	Cost of products		Cost of services		Selling, general and administrative		Other(2)		Cost of products		Cost of services		Selling, general and administrative		Other(2)

Foreign currency exchange contracts	$	(5)	$	(1)	$	—	$	—	$	13	$	4	$	—	$	—
Effects of cash flow hedges	(5)		(1)		—		—		13		4		—		—

Foreign currency exchange contracts and options	—		—		—		1		—		—		—		—
Effects of net investment hedges	—		—		—		1		—		—		—		—
Foreign currency exchange contracts	(38)		(9)		—		4		(25)		(5)		—		5



Other derivatives(1)	—		—		(2)		10		—		—		—		7
Effects of derivatives not designated as hedging instruments	$	(38)	$	(9)	$	(2)	$	14	$	(25)	$	(5)	$	—	$	12


	For the nine months ended September 30, 2023								For the nine months ended September 30, 2022
	Cost of products		Cost of services		Selling, general and administrative		Other(2)		Cost of products		Cost of services		Selling, general and administrative		Other(2)

Foreign currency exchange contracts	$	18	$	4	$	—	$	—	$	27	$	7	$	—	$	—
Effects of cash flow hedges	18		4		—		—		27		7		—		—

Foreign currency exchange contracts and options	—		—		—		1		—		—		—		—
Effects of net investment hedges	—		—		—		1		—		—		—		—
Foreign currency exchange contracts	(28)		(6)		—		10		(86)		(16)		—		12



Other derivatives(1)	—		—		5		36		—		—		—		29
Effects of derivatives not designated as hedging instruments	$	(28)	$	(6)	$	5	$	46	$	(86)	$	(16)	$	—	$	41

(1) Other derivatives are comprised of embedded derivatives, equity contracts, and commodity derivatives.

(2) Amounts inclusive of Other income (expense) – net and Interest and other financial charges – net on the Condensed Consolidated and Combined Statements of Income.

Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis

The following table represents financial assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Financial Assets and Liabilities
	As of September 30, 2023								As of December 31, 2022
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Investment securities	$	28	$	—	$	—	$	28	$	21	$	—	$	—	$	21
Derivatives	—		126		—		126		—		66		—		66
Liabilities:
Deferred compensation(1)	236		3		—		239		62		2		—		64
Derivatives	—		215		—		215		—		203		6		209
Contingent consideration	—		—		49		49		—		—		42		42

(1) Certain deferred compensation plans whose value is derived from market-based securities values were transferred from GE as part of the Spin-Off.

INCOME TAXES (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
INCOME TAXES (Details) - USD ($) $ in Millions	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Mar. 31, 2023	Jan. 03, 2023
Income Tax Disclosure [Abstract]
Effective income tax rate	39.30%	20.70%	31.40%	23.00%
Deferred tax provision, Tax Matters Agreement	$ 105		$ 105
Income tax benefit, change in tax indemnities	$ 30		$ 30
Deferred tax liabilities, undistributed foreign earnings					$ 30
Deferred tax assets, net						$ 3,099
Deferred tax assets, pension and post retirement benefits						$ 964

FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS - Effect of Derivatives Instruments on Statements of Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	$ (5)	$ 17	$ 22	$ 34
Selling, general and administrative
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of net investment hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	(2)	0	5	0
Selling, general and administrative \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	0	0	0	0
Selling, general and administrative \| Foreign currency exchange contracts and options
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
Selling, general and administrative \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	(2)	0	5	0
Other
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of net investment hedges	1	0	1	0
Effects of derivatives not designated as hedging instruments	14	12	46	41
Other \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	4	5	10	12
Other \| Foreign currency exchange contracts and options
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	1	0	1	0
Other \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	10	7	36	29
Products \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(5)	13	18	27
Effects of net investment hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	(38)	(25)	(28)	(86)
Products \| Cost of revenue \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(5)	13	18	27
Effects of derivatives not designated as hedging instruments	(38)	(25)	(28)	(86)
Products \| Cost of revenue \| Foreign currency exchange contracts and options
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
Products \| Cost of revenue \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	0	0	0	0
Services \| Cost of revenue
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(1)	4	4	7
Effects of net investment hedges	0	0	0	0
Effects of derivatives not designated as hedging instruments	(9)	(5)	(6)	(16)
Services \| Cost of revenue \| Foreign currency exchange contracts
Derivative Instruments, Gain (Loss) [Line Items]
Effects of cash flow hedges	(1)	4	4	7
Effects of derivatives not designated as hedging instruments	(9)	(5)	(6)	(16)
Services \| Cost of revenue \| Foreign currency exchange contracts and options
Derivative Instruments, Gain (Loss) [Line Items]
Effects of net investment hedges	0	0	0	0
Services \| Cost of revenue \| Other derivatives
Derivative Instruments, Gain (Loss) [Line Items]
Effects of derivatives not designated as hedging instruments	$ 0	$ 0	$ 0	$ 0

POSTRETIREMENT BENEFIT PLANS (Tables)

9 Months Ended

Sep. 30, 2023

Retirement Benefits [Abstract]

Schedule of Defined Benefit Plans

The amounts assumed by GE HealthCare on January 1, 2023, are shown in the tables below.


Accumulated Benefit Obligations and Unrecognized Gain
	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Accumulated benefit obligations	$	21,696	$	1,210	$	22,906

Unrecognized gain to be recorded in AOCI	1,258		1,223		2,481


Net Benefit Liability
	As of January 1, 2023
	Defined benefit plans		Other postretirement plans		Total
Projected benefit obligations	$	21,743	$	1,210	$	22,953
Fair value of assets	18,908		—		18,908
Net liability	$	2,835	$	1,210	$	4,045

Components of Net Periodic Expense


Components of Expense (Income)
	For the three months ended September 30
	Defined benefit plans				Other postretirement plans

	2023		2022		2023		2022
Service cost – Operating	$	14	$	4	$	2	$	—
Interest cost	290		4		15		—
Expected return on plan assets	(357)		(7)		—		—
Amortization of net loss (gain)	(28)		2		(16)		—
Amortization of prior service cost (credit)	1		(1)		(22)		—
Curtailment loss (gain)	17		—		—		—
Non-operating	$	(77)	$	(2)	$	(23)	$	—
Net periodic expense (income)	$	(63)	$	2	$	(21)	$	—



	For the nine months ended September 30
	Defined benefit plans				Other postretirement plans

	2023		2022		2023		2022
Service cost – Operating	$	43	$	14	$	6	$	—
Interest cost	872		13		45		—
Expected return on plan assets	(1,070)		(21)		—		—
Amortization of net loss (gain)	(89)		5		(48)		—
Amortization of prior service cost (credit)	(1)		(3)		(66)		—
Curtailment loss (gain)	17		—		—		—
Non-operating	$	(271)	$	(6)	$	(69)	$	—
Net periodic expense (income)	$	(228)	$	8	$	(63)	$	—

COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES - Schedule of Product Warranties (Details) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Movement in Standard and Extended Product Warranty Accrual, Increase (Decrease) [Roll Forward]
Balance at beginning of period	$ 193	$ 161
Current-year provisions	158	182
Expenditures	(159)	(151)
Other changes	(3)	(12)
Balance at end of period	$ 189	$ 180

SHARE-BASED COMPENSATION - Schedule of Stock Options Valuation Assumptions (Details) - Stock options	9 Months Ended
	Sep. 30, 2023 $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Risk free rate	3.60%
Dividend yield	0.01%
Expected volatility	26.20%
Expected term (in years)	6 years 2 months 12 days
Strike price (in dollars per share)	$ 72

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

FINANCING RECEIVABLES - Narrative (Details)	Sep. 30, 2023	Dec. 31, 2022
Financing Receivable, Past Due [Line Items]
Financing receivable, nonaccrual, percent past due	5.00%	6.00%
Over 30 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	6.00%	7.00%
Over 90 days past due
Financing Receivable, Past Due [Line Items]
Financing receivable, percent past due	5.00%	6.00%

ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS (Tables)

9 Months Ended

Sep. 30, 2023

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of Goodwill


Goodwill
	Balance as of December 31, 2022		Acquisitions		Foreign exchange and other		Balance as of September 30, 2023
Imaging(1)	$	4,409	$	16	$	(3)	$	4,422
Ultrasound	3,835		94		(6)		3,923
PCS	2,036		—		—		2,036
PDx	2,533		—		—		2,533
Total Goodwill	$	12,813	$	110	$	(9)	$	12,914

(1) Includes the acquisition of IMACTIS SAS in the second quarter of 2023.

- Definition

Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482548/350-20-55-24

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-1A

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482573/350-20-50-2

+ Details

ORGANIZATION AND BASIS OF PRESENTATION (Details) - USD ($) $ / shares in Units, $ in Millions			9 Months Ended
	Jan. 03, 2023	Dec. 31, 2022	Sep. 30, 2023
Subsidiary, Sale of Stock [Line Items]
Sale of stock, percent of stock distributed	80.10%
Sale of stock, number of shares issued	454,000,000	100
Sale of stock, price per share (in dollars per share)		$ 1.00
Net transfers from Parent, including Spin-Off-related adjustments, equity reduction	$ 2,840		$ 2,840
Separation-related adjustments, deferred compensation liability	$ 548
GE \| GE HealthCare Technologies Inc
Subsidiary, Sale of Stock [Line Items]
Ownership percentage			13.50%